

A monocyte/dendritic cell molecular signature of SARS-CoV2-related multisystem inflammatory syndrome in children (MIS-C) with severe myocarditis

Camille de Cevins, Marine Luka, Nikaïa Smith, Sonia Meynier, Aude Magérus, Francesco Carbone, Víctor García-Paredes, Laura Barnabei, Maxime Batignes, Alexandre Boullé, et al.

▶ To cite this version:

Camille de Cevins, Marine Luka, Nikaïa Smith, Sonia Meynier, Aude Magérus, et al.. A monocyte/dendritic cell molecular signature of SARS-CoV2-related multisystem inflammatory syndrome in children (MIS-C) with severe myocarditis. 2021. pasteur-03244400

HAL Id: pasteur-03244400 https://pasteur.hal.science/pasteur-03244400

Preprint submitted on 1 Jun 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 A monocyte/dendritic cell molecular signature of SARS-

2 CoV2-related multisystem inflammatory syndrome in

3 children (MIS-C) with severe myocarditis

4 Camille de Cevins^{1, 2}, Marine Luka^{1, 3, #}, Nikaïa Smith^{4, #}, Sonia Meynier^{5, #}, Aude Magérus^{5,}

⁵ [#], Francesco Carbone^{1, 3, §}, Víctor García-Paredes^{1, 3, §}, Laura Barnabei^{5, §}, Maxime Batignes¹,

6 Alexandre Boullé¹, Marie-Claude Stolzenberg⁵, Brieuc P. Pérot¹, Bruno Charbit⁶, Tinhinane

7 Fali¹, Vithura Pirabarakan⁵, Boris Sorin⁵, Quentin Riller⁵, Ghaith Abdessalem¹, Maxime

8 Beretta^{7,8}, Ludivine Grzelak⁹, Pedro Goncalves^{10,11}, James P. Di Santo^{10,11}, Hugo Mouquet^{7,8},

9 Olivier Schwartz⁹, Mohammed Zarhrate¹², Mélanie Parisot¹², Christine Bole-Feysot¹², Cécile

10 Masson¹³, Nicolas Cagnard¹³, Aurélien Corneau¹⁴, Camille Bruneau⁵, Shen-Ying

11 Zhang^{15,16}, Jean-Laurent Casanova^{15,16,17}, Brigitte Bader Meunier¹⁷, Julien Haroche¹⁸, Isabelle

12 Melki^{17,19}, Mathie Lorrot²⁰, Mehdi Oualha²¹, Florence Moulin²¹ Damien Bonnet²², Zahra

Belhadjer²², Marianne Leruez²³, Slimane Allali²⁴, Christèle Gras Leguen²⁵, Loïc de Pontual²⁶,

14 Pediatric-Biocovid Study Group, Alain Fischer^{17, 27, 28}, Darragh Duffy^{4, 6, *}, Fredéric Rieux-

15 Laucat^{5, *, \wedge}, Julie Toubiana^{24, 29, *}, Mickaël M. Ménager^{1, 3, *, \wedge}

16

17 Collaborators

18 Pediatric-Biocovid Study Group: François Angoulvant, Camille Aupiais, Fanny Bajolle,

19 Romain Basmaci, Paul Bastard, Matthieu Bendavid, Solène Blache, Stéphane Blanche,

20 Christine Bodemer, Martin Chalumeau, Lucienne Chatenou, Anne Chauviré-Drouard, Fleur

- 21 Cohen-Aubart, Agathe Debray, Simon Albert Faye, Simon Fillatreau, Jacques Fourgeaud,
- 22 Pierre Frange, Marion Grimaud, Lucile Houyel, Diala Khraiche, Hanane Kouider, Alain
- 23 Lefevre-Utile, Pierre-Louis Leger, Morgane Le Gouez, Michael Levy, Manon Marchais,

24 Soraya Matczak, Alexis Mathian, Bénédicte Neven, Perrine Parize, Olivier Pellé, Yael

25 Pinhas, Marie Pouletty, Pierre Quartier dit Maire, Sylvain Renolleau, Anne-Sophie Romain,

- 26 Laure de Saint-Blanquat, Isabelle Sermet, Melissa Taylor.
- 27

30

31

32

33

34

35

36

39

40

41

28 Affiliations29 1. University

- Université de Paris, Imagine Institute, Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Atip-Avenir Team, INSERM UMR 1163, F-75015 Paris, France.
 - 2. Molecular Biology and Genomics, Translational Sciences, Sanofi R&D, Chilly-Mazarin, France.
 - 3. Labtech Single-Cell@Imagine, Imagine Institute, INSERM UMR 1163, F-75015 Paris, France.
 - 4. Translational Immunology Lab, Department of Immunology, Institut Pasteur, F-75015 Paris, France.
- Université de Paris, Imagine Institute Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, INSERM UMR 1163, F-75015 Paris, France.
 - 6. Cytometry and Biomarkers UTechS, CRT, Institut Pasteur, F-75015, Paris
 - 7. Humoral Immunology Laboratory, Department of Immunology, Institut Pasteur, F-75015, Paris
- Humoral Immunology Laboratory, Department
 Inserm U1222, Institut Pasteur, F-75015, Paris
 - 9. Virus and Immunity Unit, Department of Virology, Institut Pasteur, F-75015, Paris
 - 10. Inserm U1223, Institut Pasteur, F-75015, Paris
 - 11. Innate Immunity Unit, Department of Immunology, Institut Pasteur, F-75015, Paris
- 42 12. Genomics Core Facility, Institut Imagine-Structure Fédérative de Recherche Necker, INSERM U1163 et INSERM US24/CNRS UMS3633, Paris Descartes Sorbonne Paris Cite University, Paris, France
- 44
 13. Bioinformatics Platform, Structure Fédérative de Recherche Necker, INSERM UMR1163, Université de Paris, Imagine Institute, Paris, France.

46	14.	Sorbonne Université, UMS037, PASS, Plateforme de cytométrie de la Pitié-Salpêtrière CyPS, F-75013				
47	45	Paris, France				
48	15.	Université de Paris, Imagine Institute, Laboratory of Human Genetics of Infectious Diseases, Necker				
49		Branch, INSERM, F-75015 Paris, France.				
50	16.	St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller				
51		University, New York, NY, USA				
52	17.	Department of Paediatric Immuno-Haematology and Rheumatology, Reference center for Rheumatic,				
53		AutoImmune and Systemic diseases in children (RAISE), Hôpital Necker-Enfants Malades, Assistance				
54		Publique - Hôpitaux de Paris (AP-HP) F-75015 Paris, France				
55	18.	Department of Immunology and Infectious disease (CIMI-Paris), Pitié-Salpêtrière University Hospital,				
56		Sorbonne université, AP-HP, F-75013 Paris, France				
57		Department of Pediatrics, Robert-Debré University Hospital, AP-HP, Université de Paris, Paris, France				
58		Department of Pediatrics, Armand-Trousseau University Hospital, AP-HP, F-75012 Paris, France				
59	21.	Pediatric Intensive Care Unit, Necker-Enfants Malades University Hospital, AP-HP, Université de				
60		Paris, F-75015 Paris, France				
61		M3C-Necker Enfants Malades, AP-HP, Paris, France				
62	23.	Virology laboratory, Necker-Enfants Malades University Hospital, AP-HP, Université de Paris, F-				
63		75015 Paris, France				
64	24.	Department of General Paediatrics and Paediatric Infectious Diseases, Necker-Enfants Malades				
65		University Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Université de Paris, F-75015				
66		Paris, France				
67		Pediatric Department, Nantes University Hospital, Nantes, FR-44000, France				
68	26.	Department of Pediatrics, Jean Verdier Hospital, Assistance Publique-Hôpitaux de Paris, Paris 13				
69		University, Bondy, France				
70	27.	Université de Paris, Imagine Institute, INSERM UMR 1163, F-75015 Paris, France.				
71	28.	Collège de France, Paris, France.				
72	29.	Institut Pasteur, Biodiversity and Epidemiology of Bacterial Pathogens, Paris, France.				
73						
74	[#] Contributed equally					
75	§ Contri	Contributed equally				
76	* Contributed equally					
77	^ Corresponding authors					
78						

79 Abstract

80 SARS-CoV-2 infection in children is generally milder than in adults, yet a proportion of cases 81 result in hyperinflammatory conditions often including myocarditis. To better understand these 82 cases, we applied a multi-parametric approach to the study of blood cells of 56 children 83 hospitalized with suspicion of SARS-CoV-2 infection. The most severe forms of MIS-C (multisystem inflammatory syndrome in children related to SARS-CoV-2), that resulted in 84 myocarditis, were characterized by elevated levels of pro-angiogenesis cytokines and several 85 86 chemokines. Single-cell transcriptomic analyses identified a unique monocyte/dendritic cell 87 gene signature that correlated with the occurrence of severe myocarditis, characterized by 88 sustained NF- κ B activity, TNF- α signaling, associated with decreased gene expression of NF- κB inhibitors. We also found a weak response to type-I and type-II interferons, 89

90 hyperinflammation and response to oxidative stress related to increased HIF-1α and VEGF
91 signaling. These results provide potential for a better understanding of disease
92 pathophysiology.

93

94 Introduction

95 In adults, critical forms of COVID-19 are typically characterized by severe pneumonia and acute respiratory distress syndrome (Wiersinga et al., 2020). In children, symptomatic COVID-96 97 19 occurs much less frequently and is milder than in adults, with multifactorial reasons for these differences (Brodin, 2020; Castagnoli et al., 2020; Gudbjartsson et al., 2020; Levy et al., 98 2020; Tagarro et al., 2020). However, in regions with high incidence of SARS-CoV-2 99 infection, some children have presented a postacute hyperinflammatory illness (Datta et al., 100 101 2020). In these cases, diagnostic evidence of recent SARS-CoV-2 infection has been consistently reported (Abrams et al., 2020; Jones et al., 2020; Toubiana et al., 2020, 2021). 102 103 This condition was named multisystem inflammatory syndrome in children (MIS-C) or 104 alternatively PIMS-TS (Pediatric Inflammatory Multisystem Syndrome Temporally 105 Associated with SARS-CoV-2)(Whittaker et al., 2020). MIS-C cases most often present with 106 symptoms similar to Kawasaki Disease (KD), an hyperinflammatory illness characterized by clinical features such as strawberry-like tongue and red and dry lips, bulbar conjunctival 107 108 injection, diffuse rash, swollen extremities and cervical lymphadenopathy (McCrindle et al., 109 2017). KD complications can develop as myocarditis or shock syndrome in a minority of cases 110 (Kanegave et al., 2009). KD is thought to be triggered by viral or bacterial pathogens but the 111 precise pathophysiological mechanisms remain elusive, with one hypothesis proposing an uncontrolled superantigen-driven inflammatory immune response (Chang et al., 2014). 112 Compared to classic KD, MIS-C occurs in patients who are older, have more often 113

gastrointestinal symptoms, myocarditis and shock syndrome, and exhibit higher levels of
inflammatory markers (Abrams et al., 2020; Datta et al., 2020; Toubiana et al., 2020, 2021).

116 Inflammatory features of MIS-C are in part overlapping with those of both KD and acute

117 SARS-CoV-2 infection in children, as well as severe COVID-19 in adults (Carter et al., 2020;

118 Consiglio et al., 2020; Datta et al., 2020; Gruber et al., 2020). Very high levels of C-reactive

119 protein (CRP), Procalcitonin (PCT) and IL-6, might reflect a strong immunological response

to a pathogenic SARS-CoV-2 superantigen (Cheng et al., 2020). Autoimmune features can also

121 be found in MIS-C patients (Gruber et al., 2020).

In order to further decipher SARS-CoV-2-related conditions in children, we have performed a detailed multi-parametric study combining sensitive cytokine measurements, deep immune cell phenotyping and transcriptomic analyses at the single-cell level on peripheral blood mononuclear cells (PBMCs).

126

127 **Results**

128 Clinical description of the cohort

The study cohort consisted of 56 children hospitalized during the first peak of the SARS-CoV-129 2 pandemic (from the 6th of April to the 30th of May), and 34 healthy controls (N=26 pediatric 130 131 and N=8 adults recruited before the COVID-19 pandemic) (Figure 1, Table S1). Among the 13 children with acute respiratory infection (Table S1, Figure S1), 9 had a confirmed SARS-132 CoV-2 infection (RT-PCR on nasopharyngeal aspiration or swab) (Acute-inf (CoV2⁺) group). 133 134 Six out of these 9 cases had pneumonia, and one had an uncomplicated febrile seizure. One patient with a history of recent bone marrow transplantation for sickle cell disease, required 135 136 intensive care support. The 4 other patients (Acute-inf (CoV2⁻) group) had pneumonia associated with a positive RT-PCR test for either *Mycoplasma pneumoniae* or
rhinovirus/enterovirus, and negative RT-PCR for SARS-CoV-2.

Forty-three children displayed features of postacute hyperinflammatory illness (Figure S1, 139 140 Table S1). SARS-CoV-2 infection status of all samples was confirmed by specific antibody 141 determination (both IgG and IgA) in the plasma, using ELISA and flow cytometry-based 142 technics as described in the methods (Figure S2A). Most (n=30) had a confirmed SARS-CoV-143 2 infection (with 14 also positive for concomitant nasopharyngeal RT-PCR testing) and were therefore considered as cases of MIS-C (MIS-C (CoV2⁺) group); all 30 cases of MIS-C 144 145 presented clinical features of KD, 14 of them fulfilled clinical criteria for a complete form of 146 KD according to the American Heart Association (McCrindle et al., 2017). Of note, 21/30 cases 147 had severe myocarditis (i.e. with elevated high-sensitivity cardiac troponin I and/or regional 148 wall motion abnormalities on echocardiography, and clinical signs of circulatory failure 149 requiring intensive care support; MIS-C_MYO (CoV2⁺)). Thirteen tested negative for SARS-CoV-2 and fulfilled clinical criteria for complete (n=6) or incomplete (n=7) Kawasaki disease 150 151 (KD), and were therefore considered to have KD-like illness (KD (CoV2⁻) group) (Figure S1, 152 Table S1). Clinical and biological characteristics, at time of disease activity and before 153 treatment, or within 24 hours of treatment onset, are presented in **Table S1**. MIS-C cases had 154 low lymphocyte counts and those with severe myocarditis had in addition abnormally increased 155 neutrophil counts as compared to other groups, along with high levels of CRP, PCT, serum alanine transaminases (ALT) and ferritin (Table S1). All cases responded favorably to 156 157 intravenous immunoglobulin injections (IVIG), some (N=12, Table S1) in combination with glucocorticosteroids, received before sampling. Multi-parametric analyses were performed at 158 159 a median fever persistence of 9-10 days (Figures 1A, B).

160

161 *Elevated inflammatory cytokine levels in pediatric acute infection and* 162 *postacute hyperinflammatory conditions*

163 We investigated plasma cytokine and chemokine levels in all patients, by Luminex and Simoa assays. Hierarchical clustering analysis and stratification by patient groups revealed overall 164 elevated levels of immune and inflammatory markers, with 40/46 measured proteins 165 166 significantly elevated (q<0.05) as compared to healthy controls (**Figure 2A**; global heat map). Twelve cytokines were found to be elevated in all groups of patients as compared to healthy 167 168 controls (Figure S2B). High IL-8 and CXCL1 (Figure S2C) were more specific to children 169 with acute infection. Cytokine levels did not significantly differ between children with acute infection with or without evidence of SARS-CoV-2 infection (Figures S2D-F). IFN γ , IFN α 2, 170 IL-17A, TNF- α , IL-10, Granzyme B, were higher in children with postacute 171 hyperinflammation (MIS-C ($CoV2^+$), MIS-C_MYO ($CoV2^+$), and KD ($CoV2^-$) groups), as 172 compared to pediatric healthy donors (CTL) and patients with acute infections (Acute-inf 173 174 $(CoV2^+)$ and Acute-inf $(CoV2^-)$ (Figure 2A, top cluster and 2B). A slightly higher expression 175 of IFNα2 and IL-17A was found in MIS-C without myocarditis (MIS-C (CoV-2⁺) patients). (Figure 2C). In contrast, 11 cytokines and chemokines (CSF2, CCL2, IL-6, CXCL10, FLT3L, 176 VEGF, TGF-A, IL-1RA, PD-L1, CX3CL1, TGF-B1) were higher in MIS-C with severe 177 178 myocarditis (*MIS-C_MYO* (*CoV-2*⁺)) (**Figures 2 C, D**). Of note, 8 of them are known to be 179 associated with TNF- α signaling. They are involved in propagation of inflammation (IL-6, IL-15), angiogenesis and vascular homeostasis (VEGF and TGF cytokines) and activation and 180 chemotaxis of myeloid cells (CCL2, CX3CL1, CXCL10) (Figure 2D) (Holbrook et al., 2019; 181 Varfolomeev and Ashkenazi, 2004). An increased level of CCL19, CCL20, CCL3 (cell 182 migration and chemotaxis) and IL-1 agonist/antagonist (IL-1β, IL-1RA) were also observed, 183 as well as increased soluble PD-L1 (Figure S2G). Another noticeably elevated cytokine was 184 CSF2, known to be involved in myeloid cell differentiation and migration (Figure 2D). 185

Altogether, high inflammatory cytokine levels were detected in both acute infection and postacute inflammatory cases. The strongest inflammatory profile was observed in MIS-C with severe myocarditis (*MIS-C_MYO* (*CoV2*⁺)) and remarkably, a similar profile was observed when comparing MIS-C without myocarditis (*MIS-C* (*CoV2*⁺)) and KD-like illness unrelated to SARS-CoV-2 (*KD* (*CoV2*⁻)). Of note, the inflammatory profile was much reduced in intensity in MIS-C cases with myocarditis under combined glucocorticosteroid and IVIG treatment, as compared to IVIG alone (**Figure S2H**).

193

Low monocyte and dendritic cell frequencies in patients with postacute hyperinflammatory illness

196 To better decipher the blood immune cell composition of each group, PBMCs were analyzed 197 by CyTOF mass spectrometry and by single-cell analyses at the transcriptomic level (SC-RNA-SEO) (Figure 1). Clustering analyses of the data obtained from CvTOF and SC-RNA-SEO 198 revealed consistent results, with most of the alterations observed in clusters composed of 199 200 monocytes or dendritic cells (Figures 3A, B; S3 A-D). The most drastic changes were a decrease in conventional Dendritic Cells (cDCs) and plasmacytoid Dendritic Cells (pDCs) in 201 patients with a postacute hyperinflammatory illness ((MIS-C MYO (CoV2⁺), MIS-C (CoV2⁺)) 202 203 and KD (CoV2⁻)). As previously reported (Gruber et al., 2020), we also observed a trend 204 towards a decrease in monocyte clusters in children with postacute hyperinflammatory illness, 205 that was found independent of SARS-CoV-2 status (Figures 3A, B; S3 A-D). Of note, some 206 heterogeneity was observed in the proportions of non-classical monocytes in $Acute-Inf(CoV2^+)$ cases. We observed additional heterogeneity in the proportions of classical and intermediate 207 208 monocytes in patients with severe myocarditis (MIS-C_MYO (CoV2⁺) (Figures 3A, B), but 209 there was no correlation with clinical data (Table S1), nor cytokine/chemokine measurements (Figures 2 and S2). Additional modifications were detected in patients with acute SARS-CoV-210

- 211 2 infection (Acute-inf ($CoV2^+$) cases), consisting of a decrease of MAIT cells and an excess of
- naïve and central memory CD4⁺ T cells (Figures 3 A, B, S3 C, D). 212

213

Overexpression of inflammatory pathways, NF-KB signaling, and metabolic 214 changes related to hypoxia in acute infection and postacute

- 215
- hyperinflammatory conditions 216

217 To gain further insight into the mechanisms behind the different forms of SARS-CoV-2 218 infection in children, we assessed pathways modulated in each group by looking at the differentially expressed genes, obtained from the SC-RNA-SEQ dataset. In patients with acute 219 220 infection (Acute-inf (CoV2⁺) and Acute-inf (CoV2⁻)), the numbers of differentially expressed genes were homogeneously distributed among monocytes/DCs, T and B cells (Figures 4A and 221 S4A). Pathway enrichment analyses (Ingenuity Pathway Analyses; IPA, QIAGEN Inc.) 222 revealed a decrease in oxidative phosphorylation, coupled with an increase of HMGB1 223 224 signaling, HIF-1 α signaling, and hypoxia signaling. Production of nitric oxide was observed in both groups of acute infections, independently of SARS-CoV-2 infection, as compared to 225 healthy controls (Figure S4B). These observations suggest a metabolic switch potentially 226 227 driven by hypoxic conditions. NF-kB signaling, VEGF signaling and inflammatory pathways 228 (type-I and type-II IFNs, IL-1, IL-6, and IL-17 signaling pathways) were also found to be overrepresented in both groups of patients (Figure S4B). 229

230 Interestingly, alterations in the same pathways were also identified in all cases of children with SARS-CoV-2-related postacute illnesses (All MIS-C (CoV2⁺): MIS-C_MYO (CoV2⁺) and MIS-231 232 C (CoV2⁺)). However, in these cases, alterations were mostly restricted to monocytes and 233 dendritic cells (Figures 4 A, B). Comparisons of genes differentially expressed between 234 children with postacute hyperinflammatory illness with or without evidence of SARS-CoV-2 235 infection (All MIS-C ($CoV2^+$) versus KD ($CoV2^-$)), did not reveal significant differences with the exception of type-I and type-II interferon signaling (Figures S4 C, D). 236

The NF-kB signaling pathway was identified to be activated in monocytes and DCs of all 237 238 patients with acute infection and postacute hyperinflammatory illness, independently of SARS-239 CoV-2 infection (Figure 5A). While monocytes and DCs of patients with acute infection (Acute-inf (CoV2⁺) and Acute-inf (CoV2⁻)) highly expressed genes of the NF- κ B complex 240 (REL, RELA, RELB, NFKB1, NFKB2; Figures 5B, D), monocytes and DCs from all MIS-C 241 patients (MIS-C_MYO (CoV2⁺) and MIS-C (CoV2⁺)) exhibited a strong decrease in the 242 expression of NF-KB inhibitors, such as TNFAIP3 (A20), TNFAIP2, NFKBIA, NFKBID, 243 244 *NFKBIE* and *NFKBIZ* (**Figures 5C, D**). Strikingly, this decrease in the expression of NF-κB inhibitors appeared to be specific to the monocytes and DCs of MIS-C patients with severe 245 246 myocarditis (MIS-C MYO (CoV2⁺)) (Figures 5 E, S5 A-D).

In conclusion, pathways dysregulated in acute infection or postacute hyperinflammatory illness, reflected an inflammatory status based on NF- κ B signaling combined with changes in metabolism driven by a hypoxic environment. In acute respiratory disease, changes in gene expression reflected involvement of all PBMCs, whereas in postacute hyperinflammatory illnesses, monocytes/DCs were the most affected populations. These results further emphasize the role of monocytes/DCs populations in MIS-C.

253

254 Molecular pathways specific to MIS-C with severe myocarditis

To gain further insight into the inflammatory phenotype of monocytes and DCs from MIS-C patients, we compared gene expression between MIS-C patients with or without severe myocarditis and healthy controls. Most gene alterations happened in monocytes/DCs (**Figure S6A and S6C**), which lead us to focus on these populations for the following analyses. Pathway enrichment performed both on IPA and EnrichR (Chen et al., 2013; Kuleshov et al., 2016) highlighted the modulation of type-I and type-II interferon signaling pathways, with the upregulation of several interferon stimulated genes (ISGs) (*JAK2*, *STAT1*, *STAT2*, *IFITM1*, *IFITM2, IFI35, IFIT1, IFIT3, MX1, IRF1*) only in the monocytes and DCs of MIS-C patients without myocarditis (**Figures 6 A, B, S6 B, D**). However, both groups of MIS-C patients showed elevated plasma IFN- α 2 and IFNγ proteins (**Figures 2A, B**). Gene expression downregulation in monocytes and DCs of MIS-C patients with severe myocarditis, included most of the MHC class II genes suggesting a decrease in antigen processing and presentation pathways (**Figures 6 C and S6D**).

Transcription factor prediction in EnrichR revealed overexpression of targets of the NF- κ B complex in MIS-C patients with severe myocarditis as compared to MIS-C without myocarditis (**Figure S6E**). This activation of NF- κ B signaling in MIS-C patients with severe myocarditis was found to be associated with the strong downregulation of NF- κ B inhibitors as shown in **Figure 5E**.

273 A strong overexpression of genes belonging to TNF- α signaling, as well as inflammatory responses, hypoxia and response to oxidative stress (HIF1A, HMOX1, HMBG1, etc.) was found 274 275 in cases with severe myocarditis (Figures 6D, E and S6E). This was associated with a 276 downregulation of genes linked with oxidative phosphorylation, nitric oxide production and 277 iNOS signaling (**Figure S6B**). TGF- β signaling and VEGF signaling were also found enriched in monocytes and DCs of patients with myocarditis and to a lesser magnitude in B cells 278 279 (Figures S6 B, E). Interestingly, an increased expression of several genes encoding S100 280 proteins and calcium-binding cytosolic proteins, all known to serve as danger signals to 281 regulate cell migration, homeostasis and inflammation, were noticed in the cases of severe 282 myocarditis (Figure S6F) (Xia et al., 2018).

To summarize, NF- κ B activation, a decreased expression of NF- κ B inhibitors, TNF- α signaling, together with a hypoxic response to oxidative stress, VEGF signaling, downregulation of MHC-II genes and low type-I and type-II IFN responses characterize the monocytes and DCs of children with MIS-C and severe myocarditis.

10

Identification of a molecular signature specific to MIS-C with severe myocarditis

To identify a potential clinical relevance of our study, we searched for a molecular signature 289 290 that correlated with the appearance of severe myocarditis among the monocytes/DCs of children with SARS-CoV-2-related MIS-C. By using several SC-RNA-SEQ comparison 291 292 strategies (Figure 7A), we identified 329 genes upregulated in monocytes and DCs of the MIS-293 C group with myocarditis (N=6) as compared to all other groups (Figure 7A). To validate this 294 molecular signature, RNA from PBMCs were sequenced from an independent group of 295 patients. A scoring system was generated, based on normalized expression represented by a Z-296 score, coupled with hierarchical clustering, in order to identify genes that were overexpressed 297 in children with myocarditis (*MIS-C_MYO* ($CoV2^+$) group) as compared to the other groups 298 (Figure S7A). Within the 329 genes identified by SC-RNA-SEQ in monocytes and DCs of patients with severe myocarditis, expression of 116 genes were found upregulated in PBMCs 299 300 from an independent group of 9 patients belonging to the MIS-C_MYO (CoV2⁺) group with 301 myocarditis (Figures 7B). From these genes, a signature score (SignatureSCORE) was 302 determined for each sample processed by Bulk-RNA-SEQ (Figure 7C). We then further developed a RankingSCORE (Figures S7 A, B) to identify the top genes that contributed the 303 304 most to the monocytes and DCs myocarditis signature. This led to the identification of a set of 25 genes that clearly segregate patients with severe myocarditis from other MIS-C and KD 305 306 (CoV2⁻) (Figure 7D). Consistently, most of these 25 genes belong to functional pathways that 307 were previously identified (Figures 6 and S6), such as inflammation, oxidative stress, TNF- α 308 and/or NF-kB signaling, and in some cases already known markers of myocarditis or MIS-C 309 and/or COVID-19, such as genes coding for S100 proteins (Figures S7 C, D).

310 **Discussion**

311 Multi-parametric analysis of peripheral blood mononuclear cells from children with acute respiratory infection and postacute hyperinflammation, collected during the COVID-19 312 pandemic, allowed to detect an inflammatory profile associated with a loss of circulating 313 314 monocytes and dendritic cells (DCs), as well as an upregulation of genes and pathways 315 involving NF-kB signaling, oxidative stress with establishment of hypoxic conditions and VEGF signaling. These pathways were upregulated in both acute and postacute groups of 316 317 patients, independently of SARS-CoV-2 infection. However, significant features of MIS-C 318 with severe myocarditis were detected specifically in monocytes and DCs including low type-I and type-II IFN responses, decreased expression of NF-kB inhibitors, increased TNF-a 319 signaling and overexpression of HIF-1 α . 320

321 Acute cases were characterized by the detection of inflammatory markers in the plasma with a 322 particularly strong elevation of IL-8 and CXCL1, two chemokines known to mediate neutrophil 323 migration to the lung (Kunkel et al., 1991; Pease and Sabroe, 2002; Sawant et al., 2015) and a modest elevation of IFN α 2 levels. These findings suggest that in some children, a suboptimal 324 325 anti-viral type-I interferon response, alongside a hyperinflammatory response (IL-6 levels and exacerbation of the NF-kB pathway), could account for SARS-CoV-2 disease with pneumonia, 326 327 as compared to the very usual benign or even asymptomatic clinical course of SARS-CoV-2 328 infection in children. This has been previously observed in severe Respiratory Syncytial Virus 329 (RSV) infections (Hijano et al., 2019).

In the postacute patients, elevated levels of plasma IFN-γ, IFNα2, IL-10, IL-15, and, to a lesser
extent, TNF-α, were found, as previously described in other cohorts (Brodsky et al., 2020;
Carter et al., 2020; Consiglio et al., 2020; Esteve-Sole et al., 2021; Gruber et al., 2020). These
findings are typical of an ongoing anti-viral immune response, not directly related to SARSCoV-2 infection. In addition, elevated chemokines such as CCL2, CCL3 and CCL4 may recruit

monocytes and DCs to tissues, possibly accounting for their reduced numbers observed in the
blood of those patients. Additional mechanisms such as apoptosis or other cell death pathways
may also be involved.

338 Cellular phenotypes that distinguish MIS-C from classical KD have been previously reported (Brodsky et al., 2020; Consiglio et al., 2020; Esteve-Sole et al., 2021). Brodin and colleagues 339 described several key differences such as elevated IL-17, IL-6 and CXCL10 that were only 340 341 observed in KD, associated with decreased naïve CD4⁺ T cells and increased central memory and effector memory CD4⁺ T cells in MIS-C. In the present study, high levels of IL-17, IL-6 342 343 and CXCL10, were both found in MIS-C and KD (CoV2⁻) groups. In addition, no major differences in CD4⁺ T cell compartments were detected. Accordingly, only a few differentially 344 expressed genes were found between the MIS-C and KD (CoV2⁻) groups. These data support 345 346 the hypothesis that MIS-C patients with KD features exhibit a molecular phenotype close to 347 the one seen in KD patients, suggesting overlapping pathogenesis mechanisms (Gruber et al., 2020). Differences observed with previous reports by Brodin and colleagues, may be due to 348 349 inclusion of only patients with criteria for complete or incomplete KD among the MIS-C cases, 350 or technical differences in the respective studies, such as time of blood sampling relative to 351 admission to hospital and medical treatments.

352 However, we did find noticeable differences in MIS-C cases with severe myocarditis with circulatory failure that required intensive care. The expression of a number of cytokines was 353 further increased in these cases, most of them related to the NF- κ B-TNF- α signaling axis. 354 355 Elevated VEGF and TGF- α and TGF- β are potential drivers of angiogenesis and vascular 356 homeostasis, whereas elevated chemokines (CCL2, CCL3, CCL20, CX3CL1, CXCL10) could 357 mediate increased cell migration towards inflamed tissues. Molecular analysis confirmed an upregulation of genes belonging to the TNF- α and NF- κ B signaling pathways that were 358 359 specifically found in monocytes and DCs of MIS-C patients with severe myocarditis. A lower 360 expression of NF-KB complex inhibitors, including TNFAIP3 (A20), TNFAIP2, NFKBIA, 361 *NFKBIZ*, was detected, suggesting a possible mechanism for NF- κ B sustained activation which could then potentially lead to exacerbated TNF- α signaling. Overall, these results point to a 362 363 potential role of monocytes and DCs in the pathogenesis of MIS-C with severe myocarditis, 364 which might not be directly driven by SARS-CoV-2 infection, but rather due to a tolerance defect in limiting a pathological immune response, as already observed for other pathogens 365 (Goodnow, 2021). It would be interesting to investigate the presence of genetic variants among 366 367 MIS-C with severe myocarditis, in genes such as TNFAIP3, as already discussed (Goodnow, 368 2021). The apparent hypoxic conditions detected in children with myocarditis, could also 369 account for the exacerbation of NF- κ B signaling. HIF-1 α , a sensor of oxidative stress, is well-370 known for being able to induce a switch from oxidative phosphorylation to glycolysis to limit 371 generation of reactive oxygen species (ROS). It can also activate NF-κB signaling (D'Ignazio and Rocha, 2016; D'Ignazio et al., 2016). Additional environmental factors and/or genetic 372 373 predispositions could also be involved. Another striking feature was the low expression of 374 genes involved in type-I and type-II interferon responses, specifically in monocytes and DCs 375 of children with myocarditis, although IFN- γ and IFN α 2 proteins were elevated in the plasma 376 of all MIS-C patients. This reduced response to type-I IFN in the most severe forms of MIS-C 377 (with myocarditis and circulatory failure) is in part reminiscent of the impaired type-I IFN 378 activity observed in the most severe forms of COVID-19 in adults (Bastard et al., 2020; Hadjadj 379 et al., 2020; Zhang et al., 2020). The search for auto-antibodies against IFN α 2 were negative 380 (data not shown) but presence of autoantibodies to ISGs (interferon stimulated genes) cannot 381 be excluded (Combes et al., 2021).

Overall, our findings depict a model, supported by previous publications (Amoah et al., 2015;
Calabrese et al., 2004; Mann Douglas L., 2001), in which myocarditis is associated with an
attenuated negative feedback loop of TNF-α-driven NF-κB activation, together with an excess

14

385 of proangiogenic cytokines and chemokines that could attract activated myeloid and T cells to 386 the myocardium tissue (Figure S8). Locally, it could lead to the production of inflammatory 387 cytokines known to promote differentiation of cardiac fibroblasts into cardiac myofibroblasts 388 (TNF-α, TGF-β, IL1-β, IL-13, IL-4, VEGF). Cardiac myofibroblasts, as previously reported, 389 may secrete chemokines leading to further activation and recruitment of myeloid cells, creating 390 a feed-forward loop of locally sustained inflammation and myocarditis (Figure S8) (Amoah et 391 al., 2015; Angelo and Kurzrock, 2007; Delprat et al., 2020; Hua Xiumeng et al., 2020; Maloney 392 and Gao, 2015).

Using SC-RNA-SEQ data, we defined a gene signature specific of SARS-CoV-2-related 393 postacute hyperinflammatory illness with severe myocarditis that was further validated by a 394 395 global transcriptomic analysis on PBMCs from an independent patient group. The genes 396 defining this signature were consistently enriched in genes associated with inflammation, TNF-397 α and NF- κ B signaling, oxidative stress and myocarditis (Figure S7C). Interestingly, among 398 these genes, the S100 proteins and the calprotectin complex (S100A8/S100A9) in particular, 399 were previously reported and proposed as biomarkers for the most severe adult form of 400 COVID-19 with acute respiratory syndrome (Figure S7D) (Silvin et al., 2020).

401 Our study has several limitations, including the relatively low number of cases in each group, 402 the lack of a comparison with asymptomatic or mildly symptomatic non-hospitalized children 403 positive for SARS-CoV-2 and a longitudinal study of children with "classic" KD enrolled 404 before the COVID-19 pandemic. All our cellular data were generated from frozen peripheral 405 mononuclear cells, which does not allow a direct assessment of neutrophils. A parallel analysis 406 of PMN (polymorphonuclear leukocytes) will be required. Endothelial and myocardiac cells 407 are at least targets of the disease but may also contribute to the pathophysiology as described 408 above. Also, additional data supporting gene expression findings will be necessary in future 409 studies. Nevertheless, our study provides further in-depth molecular analysis of MIS-C with 410 severe myocarditis. These severe forms were found to be associated with an excessive 411 activation of the TNF- α , NF- κ B signaling axis and poor response to type-I and type-II 412 interferons in monocytes and DCs, secretion of cytokines promoting angiogenesis, chemotaxis 413 and potential migration of activated myeloid cells and neutrophils in the myocardiac tissue. 414 This may help to identify potential new clinical biomarkers and open new therapeutic 415 strategies, including drugs targeting TNF- α or NF- κ B pathways.

416 **Resource Availability**

417

418 Lead Contact

- 419 Further information and requests for resources and reagents should be directed to and will be
- 420 fulfilled by the Lead Contacts, Mickaël Ménager (<u>mickael.menager@institutimagine.org</u>) and
- 421 Frédéric Rieux-Laucat (<u>frederic.rieux-laucat@inserm.fr</u>)

422 Material availability

423 This study did not generate new unique reagents.

424 Data and Code availability

The SC-RNA-SEQ data have been deposited in the Gene Expression Omnibus (GEO) database
under ID code GEO: GSE167029. The Bulk-RNA-SEQ data have been deposited under ID
code GEO: GSE167028. Both can be accessed from the series code GEO: GSE167030

428

429 Experimental Model and Subject details

430

431 **Patients and definitions**

This prospective multicenter cohort study included children (age ≤ 18 years at the time of 432 433 admission) suspected of infection with SARS-CoV-2 between April 6, 2020 and May 30, 2020. Clinical aspects of 22 of the included patients were previously reported (Toubiana et al., 2020, 434 2021). Children admitted with fever in general pediatric wards or pediatric intensive care units 435 of Tertiary French hospitals involved in the research program, suspected of SARS-CoV-2 436 437 related illness and who underwent routine nasopharyngeal swabs for SARS-CoV-2 RT-PCR (R-GENE, Argene, Biomerieux, Marcy l'Etoile) or SARS-CoV-2 IgG serology testing 438 439 (Architect SARS-CoV-2 chemiluminescent microparticle immunoassay; Abbott Core Laboratory, IL, USA), were eligible. The study was approved by the Ethics Committee (Comité 440 de Protection des Personnes Ouest IV, n° DC-2017-2987). All parents provided written 441 442 informed consent.

443 Case definition for pediatric COVID-19 acute infection was presence of fever, fatigue, neurological abnormalities, gastro-intestinal or respiratory signs, associated with a concomitant 444 nasopharyngeal swab positive for SARS-CoV-2 RT-PCR, and absence of MIS-C criteria 445 446 (Zimmermann and Curtis, 2020). Case definition for postacute hyperinflammatory illness (Figure 1) was presence of fever, laboratory evidence of inflammation and clinically severe 447 illness with multisystem involvement, during the SARS-CoV-2 epidemic period (Datta et al., 448 449 2020). This may include children with features of KD; criteria of the American Heart Association was used to define for complete (Fever > 4 days and \geq 4 principal criteria) or 450 451 incomplete KD (Fever > 4 days and 2 or 3 principal criteria, and without characteristics 452 suggestive of another diagnosis) (McCrindle et al., 2017). Among cases with postacute hyperinflammatory illness, children with a positive SARS-CoV-2 testing (RT-PCR or 453 454 serology) were considered to have MIS-C according to CDC and WHO criteria to define MIS-455 C (CDC, 2020). Patients with postacute hyperinflammatory illness, negative SARS-CoV-2 testing (RT-PCR or serology), and criteria for KD, were considered as patients with KD-like 456 457 illness. Patients with MIS-C with clinical signs of circulatory failure requiring intensive care, with elevated high-sensitivity cardiac troponin I levels (>26 ng/mL) and /or decreased cardiac 458 459 function (diastolic or systolic ventricular dysfunction at echocardiography), were considered 460 to have MIS-C with severe myocarditis (Brissaud et al., 2016; Canter Charles E. and Simpson 461 Kathleen E., 2014).

For each included patient, we collected demographic data, symptoms, results of SARS-CoV-2
testing and other laboratory tests, echocardiograms, and treatments. All patients with negative
initial serology testing were retested after an interval of at least 3 weeks (Architect SARS-CoV2 chemiluminescent microparticle immunoassay; Abbott Core Laboratory).

466 Healthy controls were recruited before the COVID-19 pandemic (before November 2019).

467

468 Samples

For each patient and healthy donor, peripheral blood samples were collected on EDTA and lithium heparin tubes. After a centrifugation of the EDTA tube at 2300rpm for 10 minutes, plasma was taken and stored at -80°C before cytokine quantification. PBMCs were isolated from the lithium heparin samples, frozen as described below and stored at -80°C and were used for both bulk and single-cell RNAseq, as well as cell phenotyping by CyTOF. The workflow is summarized in Figure 1B.

475

476 Isolation of PBMCs

477 Peripheral blood samples were collected on lithium heparin. PBMCs were isolated by density 478 gradient centrifugation (2200 rpm without break for 30 minutes) using Ficoll (Eurobio 479 Scientific, Les Ulis, France). After centrifugation, cells were washed with Phosphate-buffered 480 saline (PBS) (Thermo Fisher scientific, Illkirch, France). The pellet was resuspended in PBS and cells were centrifuged at 1900 rpm for 5 minutes. Finally, the PBMCs pellet was frozen in 481 482 a medium containing 90% of Fetal Bovine Serum (FBS) (Gibco, Thermo Fisher scientific, 483 Illkirch, France) and 10% of dimethyl sulfoxide (DMSO) (Sigma Aldrich, St. Quentin 484 Fallavier, France).

485

486 Cytokine measurements

Prior to protein analysis plasma samples were treated in a BSL3 laboratory for viral decontamination using a protocol previously described for SARS-CoV (Darnell and Taylor, 2006), which we validated for SARS-CoV-2. Briefly, samples were treated with TRITON X100 (TX100) 1% (v/v) for 2hrs at Room Temperature. IFNα2, IFNγ, IL-17A, (triplex) and IFNβ (single plex) protein plasma concentrations were quantified by Simoa assays developed with Quanterix Homebrew kits as previously described (Rodero et al., 2017). The limit of detection of these assays were 0.6 pg/mL for IFN β , 2 fg/mL for IFN α 2, 0.05 pg/ml for IFN γ and 3 pg/mL for IL17A including the dilution factor. IL-6, TNF α , and IL-10 were measured with a commercial triplex assay (Quanterix). Additional plasma cytokines and chemokines (44 analytes) were measured with a commercial Luminex multi-analyte assay (Biotechne, R&D systems).

498

499 Serology assays

SARS-CoV-2 specific antibodies were quantified using assays previously described (Grzelak et al., 2020). Briefly, a standard ELISA assay using as target antigens the extracellular domain of the S protein in the form of a trimer (ELISA tri-S) and the S-Flow assay, which is based on the recognition of SARS-CoV-2 S protein expressed on the surface of 293T cells (293T-S), were used to quantify SARS-CoV-2 specific IgG and IgA subtypes in plasma. Assay characteristics including sensitivity and specificity were previously described (Grzelak et al., 2020).

507

508 Cell Phenotyping

To perform high-dimensional immune profiling of PBMCs, we used the Maxpar[®] DirectTM 509 Immune Profiling System (Fluidigm, Inc France) with a 30-marker antibody panel, for CyTOF 510 511 (Cytometry by Time Of Flight). Briefly, 3x10⁶ PBMCs resuspended in 300 µl of MaxPar Cell Staining Buffer were incubated for 20 minutes at room temperature after addition of 3 µL of 512 513 10 KU/mL heparin solution and 5 µl of Human TruStain FcX (Biolegend Europ, Netherland). 514 Then 270 µL of the samples were directly added to the dry antibody cocktail for 30 minutes. 3 515 mL of MaxPar Water was added to each tube for an additional 10-min incubation. Three washes were performed on all the samples using MaxPar Cell Staining Buffer and they were 516 517 fixed using 1.6% paraformaldehyde (Sigma-Aldrich, France). After one wash with MaxPar Cell Staining Buffer, cells were incubated one hour in Fix and Perm Buffer with 1:1000 of
Iridium intercalator (pentamethylcyclopentadienyl-Ir (III)-dipyridophenazine, Fluidigm, Inc
France). Cells were washed and resuspended at a concentration of 1 million cells per mL in
Maxpar Cell Acquisition Solution, a high-ionic-strength solution, and mixed with 10% of EQ
Beads immediately before acquisition.

Acquisition of the events was made on the Helios mass cytometer and CyTOF software version 523 524 6.7.1014 (Fluidigm, Inc Canada) at the "Plateforme de Cytométrie de la Pitié-Salpetriere (CyPS)." An average of 500,000 events were acquired per sample. Dual count calibration, 525 526 noise reduction, cell length threshold between 10 and 150 pushes, and a lower convolution 527 threshold equal to 10 were applied during acquisition. Mass cytometry standard files produced by the HELIOS were normalized using the CyTOF Software v. 6.7.1014. For data cleaning, 4 528 parameters (centre, offset, residual and width) are used to resolve ion fusion events (doublets) 529 530 from single events from the Gaussian distribution generated by each event (Bagwell et al., 531 2020). Subsequent to data cleaning, the program produces new FCS files consisting of only 532 intact live singlet cells. These data were analyzed in FlowJo v10.7.1 using 3 plugins 533 (DownSampleV3, UMAP and FlowSOM) with R v4.0.2. To increase efficiency of the analysis, 534 samples were downsampled to 50 000 cells, using the DownSample V3 plugin. All samples 535 were concatenated and analyzed in an unsupervised manner. Anti-CD127 antibody had to be 536 excluded due to poor staining. Clustering was performed using FlowSOM (Van Gassen et al., 537 2015). The number of clusters was set to forty-five in order to overestimate the populations 538 and detect smaller subpopulations. Grid size of the self-organizing map was set to 20x20. 539 Resulting clusters were annotated as cell populations following the kit manufacturer's instruction. When several clusters were identified as the same cell types, they were 540 541 concatenated into a single cell population. For visualization purposes, UMAP was computed 542 with the UMAP pluggin (McInnes et al.) with the following parameters: metric (Euclidean),

543 nearest neighbors (15), minimum distance (0.5) and number of components (2).

544

545 Single-cell transcriptomic (SC-RNA-SEQ)

546 SC-RNA-SEQ analyses were performed on frozen PBMCs isolated from heparin blood samples. PBMCs were thawed according to 10X Genomics protocol. The SC-RNA-SEQ 547 libraries were generated using Chromium Single Cell 3' Library & Gel Bead Kit v.3 (10x 548 549 Genomics) according to the manufacturer's protocol. Briefly, cells were counted, diluted at 550 1000 cells/µL in PBS+0,04% and 20,000 cells were loaded in the 10x Chromium Controller to generate single-cell gel-beads in emulsion. After reverse transcription, gel-beads in emulsion 551 552 were disrupted. Barcoded complementary DNA was isolated and amplified by PCR. Following 553 fragmentation, end repair and A-tailing, sample indexes were added during index PCR. The 554 purified libraries were sequenced on a Novaseq 6000 (Illumina) with 28 cycles of read 1, 8 555 cycles of i7 index and 91 cycles of read 2.

556 Sequencing reads were demultiplexed and aligned to the human reference genome (GRCh38, 557 release 98, built from Ensembl sources), using the CellRanger Pipeline v3.1. Unfiltered RNA 558 UMI counts were loaded into Seurat v3.1 (Stuart et al., 2019) for quality control, data integration and downstream analyses. Apoptotic cells and empty sequencing capsules were 559 560 excluded by filtering out cells with fewer than 500 features or a mitochondrial content higher 561 than 20%. Data from each sample were log-normalized and scaled, before batch correction using Seurat's FindIntegratedAnchors. For computational efficiency, anchors for integration 562 563 were determined using all control samples as reference and patient samples were projected onto 564 the integrated controls space. On this integrated dataset, we computed the principal component 565 analysis on the 2000 most variable genes. UMAP was carried out using the 20 most significant 566 principal components (PCs), and community detection was performed using the graph-based 567 modularity-optimization Louvain algorithm from Seurat's FindClusters function with a 0.8 resolution. Cell types labels were assigned to resulting clusters based on a manually curated 568 569 list of marker genes as well as previously defined signatures of the well-known PBMCs 570 subtypes (Monaco et al., 2019). Despite filtering for high quality cells, five clusters out of the twenty-six stood out as poor quality clusters and were removed from further analysis, namely: 571 one erythroid-cell contamination; one low UMI cluster from a single control; two clusters of 572 573 proliferating cells originating from a patient with EBV co-infection and one megakaryocytes 574 cluster. In total 152,201 cells were kept for further analysis.

After extraction and reclustering of high-quality cells, differential expression was performed separately on all PBMCs, Monocytes/DCs, T cells or B cells. Differential expression testing was conducted using the FindMarkers function of Seurat on the RNA assay with default parameters. Genes with log(FC) > 0.25 and adjusted p-values ≤ 0.05 were selected as significant.

580

581 Bulk RNA-sequencing (Bulk-RNA-SEQ)

582 Bulk-RNA-SEQ analyses were performed on frozen PBMCs extracted from heparin samples. RNA was extracted from PBMCs following the instructions of RNeasyR Mini kit (Qiagen, 583 584 Courtaboeuf, France). To note, the optional step with the DNase was performed. RNA integrity 585 and concentration were assessed by capillary electrophoresis using Fragment Analyzer 586 (Agilent Technologies). RNAseq libraries were prepared starting from 100 ng of total RNA using the Universal Plus mRNA-Seq kit (Nugen) as recommended by the manufacturer. The 587 588 oriented cDNA produced from the poly-A+ fraction was sequenced on a NovaSeq6000 from 589 Illumina (Paired-End reads 100 bases + 100 bases). A total of ~50 millions of passing-filters paired-end reads was produced per library. 590

591 Paired-end RNA-seq reads were aligned to the human Ensembl genome GRCh38.91 using 592 Hisat2 (v2.0.4)(Kim et al., 2019) and counted using featureCounts from the Subread R 593 package. The raw count matrix was analyzed using DESeq2 (version 1.28.1) (Love et al., 594 2014). No pre-filtering was applied to the data. Differential expression analysis was performed using the "DESeq" function with default parameters. For visualization and clustering, the data 595 596 was normalized using the `variant stabilizing transformation` method implemented in the "vst" 597 function. Plots were generated using ggplot2 (version 3.3.2), and pheatmap (version 1.0.12). During exploratory analyses, it was noted that the clustering was mainly driven by the sex of 598 599 the patients. To remove this effect, it was included in the regression formula for DESeq (~sex 600 + groups), and then removed following vst transformation, using "removeBatchEffect" from 601 the "limma" package (version 3.44.3).

602

603 Gene signature analysis

604 To identify genes that could be used as markers of severe myocarditis in the SC-RNA-SEQ 605 dataset, three initial strategies were used, all based on differential expression and selection of the upregulated genes. First, we performed the differential expression between MIS-C_MYO 606 607 $(CoV2^+)$ samples and all other samples. Second, differential analysis was computed between 608 MIS-C MYO ($CoV2^+$) and other samples with postacute hyperinflammatory illness. In the last 609 strategy, we selected genes that were upregulated between the MIS-C_MYO ($CoV2^+$) and the 610 CTL, but not upregulated in any other group compared to the CTL (Figure 7A). These three 611 strategies allowed us to identify 329 unique genes.

To further explore whether these genes could be considered as markers of severe myocarditis, we analyzed their expression profile in our bulk RNA-SEQ dataset. This dataset excluded samples from patients of the *MIS-C_MYO* ($CoV2^+$) that were included in the SC-RNA-SEQ cohort. Vst-transformed counts were log2-normalized and converted to z-score using the scale 616 function in R (v 4.0.2). A GeneSCORE was computed for each group as the mean z-score of the samples of a group. Heatmaps representing this GeneSCORE_{group} were performed using 617 618 pheatmap. Hierarchical clustering of the 329 previously identified genes was performed using 619 the complete method on the distance measured using Pearson's correlation, as implemented by 620 pheatmap. The hierarchical clustering was divided into 15 main clusters, 4 of which had the expected pattern of expression: Clusters that had a higher expression in MIS-C_MYO (CoV2⁺) 621 622 than any other group were selected, resulting in 116 genes. A signature score for each sample 623 was performed on these genes, corresponding to the mean expression (z-score) of these N genes 624 in each sample (SignatureSCORE).

625 These genes were subsequently ranked based on the following equation:

- RankingSCORE 626
- 627

628 + $GeneSCORE_{KD (CoV2-)})$

629 where the SCOREs represent the mean expression (z-score) in each disease groups, and the 630 SignatureScore was computed on the top 25 genes.

 $= GeneSCORE_{MIS-C_MYO(COV2+)} - (GeneSCORE_{MIS-C(COV2+)})$

631

Quantification and statistical analysis 632

Cytokine heatmaps were made with Qlucore OMICS explore (version 3.5(26)) and dot plots 633 634 with GraphPad Prism (version 8). Differentially secreted cytokines were included in the heat 635 maps based on a 1.5 Fold Change (FC) comparison between groups as indicated. Dot plot 636 differences between each group were identified by Kruskal-Wallis tests followed by post-hoc 637 multiple comparison Dunn's test.

Statistical tests for cellular composition analysis in both the CyTOF and SC-RNA-SEQ 638 datasets were performed in R v3.6.1. Kruskal-Wallis test followed by post-hoc multiple 639

640 comparison Dunn's test was applied to assess differences in cell population proportions (*: p
641 ≤0.05; **: p ≤0.01; ***: p ≤0.001).

Differential expression testing in the SC-RNA-SEQ dataset was conducted using the 642 643 FindMarkers function in Seurat, with default Wilcoxon testing. P-values were controlled using 644 Bonferroni correction. Genes with an absolute $log(fold-change) \ge 0.25$ and an adjusted p-value ≤0.05 were selected as differentially expressed. Pathways analysis was performed using both 645 646 the Ingenuity pathway analysis v57662101 software (IPA (QIAGEN Inc.) and EnrichR (Chen et al., 2013; Kuleshov et al., 2016). Heatmaps were extracted from the comparison module in 647 648 IPA. Pathways with an absolute z-score lower than 2 or a Bonferroni-Hochberg corrected p-649 values higher than 0.05 were filtered out. Reactome 2016 and Molecular Signature DataBase Hallmark 2020 (MSigDB Hallmark 2020) pathway enrichment analysis were performed using 650 651 EnrichR. The TRRUST transcription factors 2019 (Han et al., 2018) used for the transcription 652 factors enrichment analysis was performed using Enrich R.

653 Author contributions:

654 CdC, ML, SM, AM, NS, FC, VGP, LB generated and analyzed data. MB, AB, BPP, GA,

- 655 TF analyzed data. MB, LG, PG, JDS, HM, OS, CB, PB, and JLC generated data. CdC,
- 656 ML, AF design figures and wrote manuscript. DD, FRL, JT and MMM conceived the
- 657 study, analyzed data, wrote the manuscript and supervised the study.
- 658

659 Acknowledgements:

660 The study was supported by the Institut National de la Santé et de la Recherche Médicale 661 (INSERM), by the "URGENCE COVID-19" fundraising campaign of Institut Pasteur, by the Atip-Avenir, Emergence ville de Paris program and fond de dotation Janssen Horizon and by 662 663 government grants managed by the Agence National de la Recherche as part of the "Investment for the Future" program (Institut Hospitalo-Universitaire Imagine, grant ANR-10-IAHU-01, 664 Recherche Hospitalo-Universitaire, grant ANR-18-RHUS-0010, Laboratoire d'Excellence 665 "Milieu Intérieur", grant ANR-10-LABX-69-01), the Centre de Référence Déficits 666 Immunitaires Héréditaires (CEREDIH), the Agence National de la Recherche (ANR-flash 667 Covid19 "AIROCovid" to FRL and "CoVarImm" to DD and JDS), and by the FAST 668 669 Foundation (French Friends of Sheba Tel Hashomer Hospital). The LabTech Single-670 Cell@Imagine is supported by the Paris Region and the "Investissements d'avenir" program 671 through the 2019 ATF funding – Sésame Filières PIA (Grant N°3877871).

672 CdC is the recipient of a CIFRE-PhD (Sanofi). L.B. was a recipient of an Imagine institute PhD international program supported by the Fondation Bettencourt Schueller. L.B. was also 673 674 supported by the EUR G.E.N.E. (reference #ANR-17-EURE-0013) and is part of the Université 675 de Paris IdEx #ANR-18-IDEX-0001 funded by the French Government through its 676 "Investments for the Future" program. S.M. was a recipient of an INSERM and Institut Imagine 677 post-doctorat program supported by the Fondation pour la Recherche Médicale (FRM 678 N°SPF20170938825). NS was a recipient of the Pasteur-Roux-Cantarini Fellowship. VGP obtained an Imagine international PhD fellowship program supported by the Fondation 679 Bettencourt Schueller. BPP is the recipient of an ANRS post-doctoral fellowship. We thank 680 681 *Imagine* genomic, bioinformatic and single-cell core facilities, the Institut Pasteur Cytometry 682 and Biomarkers UTechS platform and the Pitié-Salpêtrière Cytometry platform CyPS.

683 **References**

- Abrams, J.Y., Godfred-Cato, S.E., Oster, M.E., Chow, E.J., Koumans, E.H., Bryant, B., Leung,
 J.W., and Belay, E.D. (2020). Multisystem Inflammatory Syndrome in Children Associated
 with Severe Acute Respiratory Syndrome Coronavirus 2: A Systematic Review. J Pediatr 226,
 45-54.e1.
- Amoah, B.P., Yang, H., Zhang, P., Su, Z., and Xu, H. (2015). Immunopathogenesis of
 Myocarditis: The Interplay Between Cardiac Fibroblast Cells, Dendritic Cells, Macrophages
 and CD4+T Cells. Scandinavian Journal of Immunology *82*, 1–9.
- Angelo, L.S., and Kurzrock, R. (2007). Vascular Endothelial Growth Factor and Its
 Relationship to Inflammatory Mediators. Clin Cancer Res *13*, 2825–2830.
- 693 Bagwell, C.B., Inokuma, M., Hunsberger, B., Herbert, D., Bray, C., Hill, B., Stelzer, G., Li, S.,
- Kollipara, A., Ornatsky, O., et al. (2020). Automated Data Cleanup for Mass Cytometry.
 Cytometry A *97*, 184–198.
- 696 Bastard, P., Rosen, L.B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham, K.,
- 697 Philippot, Q., Rosain, J., Béziat, V., et al. (2020). Autoantibodies against type I IFNs in
- 698 patients with life-threatening COVID-19. Science *370*.
- Brissaud, O., Botte, A., Cambonie, G., Dauger, S., de Saint Blanquat, L., Durand, P., Gournay,
- V., Guillet, E., Laux, D., Leclerc, F., et al. (2016). Experts' recommendations for the
 management of cardiogenic shock in children. Ann Intensive Care 6, 14.
- 702 Brodin, P. (2020). Why is COVID-19 so mild in children? Acta Paediatr *109*, 1082–1083.
- Brodsky, N.N., Ramaswamy, A., and Lucas, C.L. (2020). The Mystery of MIS-C Post-SARS-CoV2 Infection. Trends in Microbiology *28*, 956–958.
- 705 Calabrese, F., Carturan, E., Chimenti, C., Pieroni, M., Agostini, C., Angelini, A., Crosato, M.,
- Valente, M., Boffa, G.M., Frustaci, A., et al. (2004). Overexpression of tumor necrosis factor
- 707 (TNF) α and TNF α receptor I in human viral myocarditis: clinicopathologic correlations.
 708 Modern Pathology *17*, 1108–1118.
- Canter Charles E. and Simpson Kathleen E. (2014). Diagnosis and Treatment of Myocarditis
 in Children in the Current Era. Circulation *129*, 115–128.
- 711 Carter, M.J., Fish, M., Jennings, A., Doores, K.J., Wellman, P., Seow, J., Acors, S., Graham, C.,
- 712 Timms, E., Kenny, J., et al. (2020). Peripheral immunophenotypes in children with
- 713 multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nature
- 714 Medicine *26*, 1701–1707.
- 715 Castagnoli, R., Votto, M., Licari, A., Brambilla, I., Bruno, R., Perlini, S., Rovida, F., Baldanti, F.,
- and Marseglia, G.L. (2020). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- 717 Infection in Children and Adolescents: A Systematic Review. JAMA Pediatr 174, 882–889.

718 CDC (2020). Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with719 Coronavirus Disease 2019 (COVID-19).

Chang, L.-Y., Lu, C.-Y., Shao, P.-L., Lee, P.-I., Lin, M.-T., Fan, T.-Y., Cheng, A.-L., Lee, W.-L., Hu,
J.-J., Yeh, S.-J., et al. (2014). Viral infections associated with Kawasaki disease. J Formos Med
Assoc *113*, 148–154.

- 723 Chen, E.Y., Tan, C.M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G.V., Clark, N.R., and Ma'ayan,
- A. (2013). Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool.
- 725 BMC Bioinformatics 14, 128.
- Cheng, M.H., Zhang, S., Porritt, R.A., Rivas, M.N., Paschold, L., Willscher, E., Binder, M.,
 Arditi, M., and Bahar, I. (2020). Superantigenic character of an insert unique to SARS-CoV-2
 spike supported by skewed TCR repertoire in patients with hyperinflammation. PNAS *117*,
 25254–25262.
- Combes, A.J., Courau, T., Kuhn, N.F., Hu, K.H., Ray, A., Chen, W.S., Chew, N.W., Cleary, S.J.,
 Kushnoor, D., Reeder, G.C., et al. (2021). Global absence and targeting of protective immune
 states in severe COVID-19. Nature 1–10.
- Consiglio, C.R., Cotugno, N., Sardh, F., Pou, C., Amodio, D., Rodriguez, L., Tan, Z., Zicari, S.,
 Ruggiero, A., Pascucci, G.R., et al. (2020). The Immunology of Multisystem Inflammatory
- 735 Syndrome in Children with COVID-19. Cell *183*, 968-981.e7.
- Darnell, M.E.R., and Taylor, D.R. (2006). Evaluation of inactivation methods for severe acute
 respiratory syndrome coronavirus in noncellular blood products. Transfusion *46*, 1770–
 1777.
- Datta, S.D., Talwar, A., and Lee, J.T. (2020). A Proposed Framework and Timeline of the
 Spectrum of Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public
 Health Implications. JAMA *324*, 2251–2252.
- 742 Delprat, V., Tellier, C., Demazy, C., Raes, M., Feron, O., and Michiels, C. (2020). Cycling
- 743 hypoxia promotes a pro-inflammatory phenotype in macrophages via JNK/p65 signaling
 744 pathway. Scientific Reports *10*, 882.
- 745 D'Ignazio, L., and Rocha, S. (2016). Hypoxia Induced NF-κB. Cells 5.
- D'Ignazio, L., Bandarra, D., and Rocha, S. (2016). NF-κB and HIF crosstalk in immune
 responses. FEBS J *283*, 413–424.
- 748 Esteve-Sole, A., Anton, J., Pino-Ramírez, R.M., Sanchez-Manubens, J., Fumadó, V., Fortuny,
- 749 C., Rios-Barnes, M., Sanchez-de-Toledo, J., Girona-Alarcón, M., Mosquera, J.M., et al. (2021).
- 750 Similarities and differences between the immunopathogenesis of COVID-19-related
- 751 pediatric inflammatory multisystem syndrome and Kawasaki disease. J Clin Invest.

<sup>Goodnow, C.C. (2021). COVID-19, varying genetic resistance to viral disease and immune
tolerance checkpoints. Immunology & Cell Biology</sup> *99*, 177–191.

- 754 Gruber, C.N., Patel, R.S., Trachtman, R., Lepow, L., Amanat, F., Krammer, F., Wilson, K.M.,
- 755 Onel, K., Geanon, D., Tuballes, K., et al. (2020). Mapping Systemic Inflammation and
- 756 Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell 183,
- 757 982-995.e14.
- 758 Grzelak, L., Temmam, S., Planchais, C., Demeret, C., Tondeur, L., Huon, C., Guivel-
- 759 Benhassine, F., Staropoli, I., Chazal, M., Dufloo, J., et al. (2020). A comparison of four
- serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from
- 761 different populations. Sci Transl Med *12*.
- 762 Gudbjartsson, D.F., Helgason, A., Jonsson, H., Magnusson, O.T., Melsted, P., Norddahl, G.L.,
- 763 Saemundsdottir, J., Sigurdsson, A., Sulem, P., Agustsdottir, A.B., et al. (2020). Spread of
- 764 SARS-CoV-2 in the Icelandic Population. N Engl J Med *382*, 2302–2315.
- 765 Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B.,
- 766 Bondet, V., Chenevier-Gobeaux, C., et al. (2020). Impaired type I interferon activity and
- inflammatory responses in severe COVID-19 patients. Science *369*, 718–724.
- Han, H., Cho, J.-W., Lee, S., Yun, A., Kim, H., Bae, D., Yang, S., Kim, C.Y., Lee, M., Kim, E., et al.
- 769 (2018). TRRUST v2: an expanded reference database of human and mouse transcriptional
 770 regulatory interactions. Nucleic Acids Res *46*, D380–D386.
- Hijano, D.R., Vu, L.D., Kauvar, L.M., Tripp, R.A., Polack, F.P., and Cormier, S.A. (2019). Role of
 Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and
- 773 Disease Severity. Front Immunol 10.
- Holbrook, J., Lara-Reyna, S., Jarosz-Griffiths, H., and McDermott, M.F. (2019). Tumour
 necrosis factor signalling in health and disease. F1000Res 8.
- Hua Xiumeng, Hu Gang, Hu Qingtao, Chang Yuan, Hu Yiqing, Gao Linlin, Chen Xiao, Yang
- Ping-Chang, Zhang Yu, Li Mingyao, et al. (2020). Single-Cell RNA Sequencing to Dissect the
- 778 Immunological Network of Autoimmune Myocarditis. Circulation *142*, 384–400.
- Jones, V.G., Mills, M., Suarez, D., Hogan, C.A., Yeh, D., Segal, J.B., Nguyen, E.L., Barsh, G.R.,
 Maskatia, S., and Mathew, R. (2020). COVID-19 and Kawasaki Disease: Novel Virus and
 Novel Case. Hosp Pediatr *10*, 537–540.
- Kanegaye, J.T., Wilder, M.S., Molkara, D., Frazer, J.R., Pancheri, J., Tremoulet, A.H., Watson,
 V.E., Best, B.M., and Burns, J.C. (2009). Recognition of a Kawasaki disease shock syndrome.
 Pediatrics *123*, e783-789.
- Kim, D., Paggi, J.M., Park, C., Bennett, C., and Salzberg, S.L. (2019). Graph-based genome
 alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol *37*, 907–915.
- Kuleshov, M.V., Jones, M.R., Rouillard, A.D., Fernandez, N.F., Duan, Q., Wang, Z., Koplev, S.,
 Jenkins, S.L., Jagodnik, K.M., Lachmann, A., et al. (2016). Enrichr: a comprehensive gene set
 enrichment analysis web server 2016 update. Nucleic Acids Res 44, W90-97.

- Kunkel, S.L., Standiford, T., Kasahara, K., and Strieter, R.M. (1991). Interleukin-8 (IL-8): the
 major neutrophil chemotactic factor in the lung. Exp Lung Res *17*, 17–23.
- Levy, C., Basmaci, R., Bensaid, P., Bru, C.B., Coinde, E., Dessioux, E., Fournial, C., Gashignard,
 J., Haas, H., Hentgen, V., et al. (2020). Changes in RT-PCR-positive SARS-CoV-2 rates in adults
 and children according to the epidemic stages. MedRxiv 2020.05.18.20098863.
- Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and
 dispersion for RNA-seq data with DESeq2. Genome Biol *15*, 550.
- Maloney, J.P., and Gao, L. (2015). Proinflammatory Cytokines Increase Vascular Endothelial
 Growth Factor Expression in Alveolar Epithelial Cells (Hindawi).
- Mann Douglas L. (2001). Tumor Necrosis Factor and Viral Myocarditis: The Fine Line
 Between Innate and Inappropriate Immune Responses in the Heart. Circulation *103*, 626–
 629.
- 802 McCrindle, B.W., Rowley, A.H., Newburger, J.W., Burns, J.C., Bolger, A.F., Gewitz, M., Baker,
- 803 A.L., Jackson, M.A., Takahashi, M., Shah, P.B., et al. (2017). Diagnosis, Treatment, and Long-
- 804 Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals
- 805 From the American Heart Association. Circulation *135*, e927–e999.
- McInnes, L., Healy, J., and Melville, J. UMAP: Uniform Manifold Approximation andProjection for Dimension Reduction. 63.
- 808 Monaco, G., Lee, B., Xu, W., Mustafah, S., Hwang, Y.Y., Carré, C., Burdin, N., Visan, L.,
- Ceccarelli, M., Poidinger, M., et al. (2019). RNA-Seq Signatures Normalized by mRNA
 Abundance Allow Absolute Deconvolution of Human Immune Cell Types. Cell Rep *26*, 1627-
- 811 1640.e7.
- Pease, J.E., and Sabroe, I. (2002). The Role of Interleukin-8 and its Receptors in
 Inflammatory Lung Disease. Am J Respir Med *1*, 19–25.
- 814 Rodero, M.P., Decalf, J., Bondet, V., Hunt, D., Rice, G.I., Werneke, S., McGlasson, S.L.,
- Alyanakian, M.-A., Bader-Meunier, B., Barnerias, C., et al. (2017). Detection of interferon
- alpha protein reveals differential levels and cellular sources in disease. J Exp Med 214,
- 817 1547–1555.
- 818 Sawant, K.V., Xu, R., Cox, R., Hawkins, H., Sbrana, E., Kolli, D., Garofalo, R.P., and
- Rajarathnam, K. (2015). Chemokine CXCL1-Mediated Neutrophil Trafficking in the Lung: Role
 of CXCR2 Activation. J Innate Immun 7, 647–658.
- 821 Silvin, A., Chapuis, N., Dunsmore, G., Goubet, A.-G., Dubuisson, A., Derosa, L., Almire, C.,
- 822 Hénon, C., Kosmider, O., Droin, N., et al. (2020). Elevated Calprotectin and Abnormal
- 823 Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. Cell *182*, 1401-1418.e18.
- Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W.M., Hao, Y.,
- 825 Stoeckius, M., Smibert, P., and Satija, R. (2019). Comprehensive Integration of Single-Cell
- 826 Data. Cell *177,* 1888-1902.e21.

- Tagarro, A., Epalza, C., Santos, M., Sanz-Santaeufemia, F.J., Otheo, E., Moraleda, C., and
- Calvo, C. (2020). Screening and Severity of Coronavirus Disease 2019 (COVID-19) in Children
 in Madrid, Spain. JAMA Pediatr.
- 830 Toubiana, J., Poirault, C., Corsia, A., Bajolle, F., Fourgeaud, J., Angoulvant, F., Debray, A.,
- Basmaci, R., Salvador, E., Biscardi, S., et al. (2020). Kawasaki-like multisystem inflammatory
 syndrome in children during the covid-19 pandemic in Paris, France: prospective
- observational study. BMJ *369*, m2094.
- Toubiana, J., Cohen, J.F., Brice, J., Poirault, C., Bajolle, F., Curtis, W., Moulin, F., Matczak, S., Leruez, M., Casanova, J.-L., et al. (2021). Distinctive Features of Kawasaki Disease Following
- 836 SARS-CoV-2 Infection: a Controlled Study in Paris, France. J Clin Immunol.
- 837 Van Gassen, S., Callebaut, B., Van Helden, M.J., Lambrecht, B.N., Demeester, P., Dhaene, T.,
- and Saeys, Y. (2015). FlowSOM: Using self-organizing maps for visualization and
- 839 interpretation of cytometry data. Cytometry A *87*, 636–645.
- Varfolomeev, E.E., and Ashkenazi, A. (2004). Tumor Necrosis Factor: An Apoptosis JuNKie?
 Cell *116*, 491–497.
- 842 Whittaker, E., Bamford, A., Kenny, J., Kaforou, M., Jones, C.E., Shah, P., Ramnarayan, P.,
- Fraisse, A., Miller, O., Davies, P., et al. (2020). Clinical Characteristics of 58 Children With a
 Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2.
 JAMA 324, 259–269.
- 846 Wiersinga, W.J., Rhodes, A., Cheng, A.C., Peacock, S.J., and Prescott, H.C. (2020).
- Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019
 (COVID-19): A Review. JAMA *324*, 782–793.
- Xia, C., Braunstein, Z., Toomey, A.C., Zhong, J., and Rao, X. (2018). S100 Proteins As an
 Important Regulator of Macrophage Inflammation. Front. Immunol. 8.
- Zhang, Q., Bastard, P., Liu, Z., Pen, J.L., Moncada-Velez, M., Chen, J., Ogishi, M., Sabli, I.K.D.,
- Hodeib, S., Korol, C., et al. (2020). Inborn errors of type I IFN immunity in patients with lifethreatening COVID-19. Science *370*.
- Zimmermann, P., and Curtis, N. (2020). Coronavirus Infections in Children Including COVID-
- 19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and
- 856 Prevention Options in Children. Pediatr Infect Dis J *39*, 355–368.

857




Figure 1: Timeline and experimental designs. A. Timeline depicting when the different groups of pediatric patients were enrolled. **B.** Description of the different types of analyses performed on whole blood samples, peripheral blood mononuclear cells (PBMCs) and plasma. CyTOF: Mass cytometry (Cytometry by Time Of Flight). SC-RNA-SEQ: single-cell transcriptomic followed by sequencing. Bulk-RNA-SEQ: transcriptomic bulk level sequencing. Simoa: Single molecule array, digital ELISA. Luminex: cytokine bead array assays. Ig dosage; quantification of SARS-CoV-2 specific immunoglobulins. CTL, healthy donors, in green; Acute-inf (CoV2⁻), patients with acute respiratory infection but no evidence of SARS-CoV-2 infection, in gray; Acute-inf $(CoV2^+)$, patients with acute respiratory infection and evidence of SARS-CoV-2 infection, in blue; *MIS-C* ($CoV2^+$), patients with postacute multi-inflammatory syndrome and evidence of SARS-CoV-2 infection, in orange; MIS-C_MYO (CoV2⁺), patients with postacute hyperinflammatory syndrome, severe myocarditis and evidence of SARS-CoV-2 infection, in red; KD ($CoV2^{-}$), patients with postacute hyperinflammatory syndrome, no evidence of SARS-CoV-2 infection, but criteria for Kawasaki Disease (KD), in pink. Illustrations were obtained from Servier Medical Art, licensed under a Creative Common Attribution 3.0 Generic License. http://smart.servier.com/.

Diagnosis	Acute infection		Postacute hyperinflammatory illness		
Groups of patients ¹	Acute-Inf (CoV2 ⁻) n=4	Acute-Inf (CoV2+) n= 9	MIS-C (CoV2 ⁺) n=9	MIS-C_MYO (CoV2 ⁺) n=21	KD (CoV2 ⁻) n=13
General					
Male : Female	1:3	6:3	4:5	10:11	6:7
Age; median (range)	5.8 (0.8-16.1)	0.3 (0.05-12)	5.1 (0.5-15)	8.4 (1.7-16.8)	2.3 (0.7-7.2)
Comorbidities	None	1 (BMT)	None	None	None
Clinical features					
	4 (100)	9 (100)	9 (100)	21 (100)	13 (100)
Fever	4 (100)	9 (100)	1 (11)	7 (33)	2 (15)
Respiratory manifestations	4 (100)	6 (67)	1 (11)	7 (33)	2 (15)
Pneumonia	0	1 (11)	6 (67)	19 (95)	6 (46)
Gastrointestinal symptoms	1 (25)	6 (67)	1 (11)	6 (29)	0
Neurological symptoms	N/A	N/A	4 (44)	10 (48)	6 (46)
KD criteria complete	0	1 (11)	2 (22)	21 (100)	1 (8)
Admission to the intensive care unit	N/A	N/A	0	21 (100)	0
Ventricular dysfunction ²			-		-
Coronary artery dilation or aneurysm ³	N/A	N/A	1 (11)	3 (14)	1 (8)
ciological features ⁴					
Positive NP SARS-CoV-2 RT-PCR	0	9 (100)	4 (44)	10 (48)	0
Positive serum SARS-CoV-2 IgG (Abbott)	0/1 (0)	N/D	9 (100)	21 (100)	0
(Abbott) Troponin I; Median (range) (ref <26 ng/L)	N/D	N/D	10 (10-122) 5	324 (30-6900)	51 (10-93) ⁵
(ref <26 ng/L) Leukocytes x 10 ⁹ /L; Median (range) (ref 5.5-15.5)	N/D	N/D	12.3 (5.6-44)	18.9 (8-42.8)	13.7 (3.3-17.6)
Neutrophils x 10 ⁹ /L; Median (range) (ref 1.8-8.0)	1.6 (1.2-14.5)	1.5 (0.6-7.5)	7.7 (0.2-39)	14.9 (6.0-36.4)	6.5 (0.8-6.4)
Lymphocytes x 10 ⁹ /L; Median (range)	2.7 (2.1-3.4)	2.6 (0.3-7.6)	1.4 (0.6-5.6)	1.0 (0.4-3.7)	2.6 (0.8-6.4)
(ref 1.5-6.5) CRP, mg/L; Median (range)	8 (4-16)	7 (4-32)	190 (90-287)	295 (159-448)	161 (31-309)
(ref <6.0) PCT, ng/mL; Median (range)	0.2 (0.02-0.2)	0.16 (0.0922)	4.1 (0.2-152)	26.0 (1.7-299)	1.0 (0.1-5.5)
(ref <0.5) Sodium, mmol/L; Median (range) (ref 136-146)	N/D	131 (130-136)	132 (124-136)	130 (116-135)	135 (133-136)
Albumin, g/L; Median (range) (ref 35-50)	N/D	N/D	23 (15-41)	20 (16-26)	31 (25-40)
ALT, U/L; Median (range)	N/D	N/D	28 (6-146)	70 (12-257)	18 (11-277)
(ref 7-40) Ferritin µg/L; Median (range) (ref	N/D	N/D	336 (118-1400) 5	1123 (172-4490) 5	183 (139-390) 5
<i>Treatments</i>				1	
Vasoactive or inotropic agents	0	0	0	17 (81)	0
Antibiotic therapy	3 (64)	3 (33)	5 (56)	21 (100)	4 (31)
IVIG /IVIG before sampling	0	0	8 (89) / 7 (78)	21 (100) / 20 (95)	12 (92) / 11 (85)
Corticosteroids / corticosteroids before sampling	0	0	2 (22) /1 (11)	10 (48) / 7 (33)	4 (31) / 4 (31)
	0	1 (tociluzimab)	0	0	0

¹ Values are numbers (percentages) unless stated otherwise; ² ventricular dysunfunction observed at echocardiography; ³ Coronary artery abnormalities observed during hospitalization, Coronary artery dilation was defined as a coronary artery diameter z-score on echocardiography between 2.0 and 2.5, and aneurysm as a z-score \geq 2.5 (McCrindle et al., 2017); ⁴ the most abnormal values before treatment or within 24 hours of treatment onset; ⁵ missing values; BMT: bone marrow transplantation; ALT: alanine transferase; IVIG: intravenous immunoglobulins; N/A : non applicable; N/D: not determined; Ref: reference interval.

Table S1. Clinical and biological features of pediatric patients enrolled. All children and adolescents included in the study were suspected of SARS-CoV-2 illness between April 6, 2020 and May 30, 2020 and displayed either an acute respiratory infection or a postacute inflammatory illness.




Figure S1: Flowchart describing the patients enrolled. Related to Figure 1. Each group with a name in bold and a color associated corresponds to a group of patients analyzed in this study. Names and colors are used throughout the manuscript. "N" represents the number of patients enrolled in each group.




Figure 2

Figure 2: Analyses of cytokine plasma levels. A. Heatmap of the cytokines differentially secreted between the different clinical groups: CTL, green; *Acute-inf* (*CoV2*⁻), gray; *Acute-inf* (*CoV2*⁺), blue; *MIS-C* (*CoV2*⁺), orange; *MIS-C_MYO* (*CoV2*⁺), red; *KD* (*CoV2*⁻), pink). On the x axis, blood donors are organized by groups and on the y axis, cytokines are displayed following hierarchical clustering. Cytokines were expressed as pg/ml and log transformed with blue to orange colors representing lower to higher expression respectively. **B.** Dot plots of cytokines elevated in postacute hyper inflammatory groups (*MIS-C* (*CoV2*⁺), *MIS-C_MYO* (*CoV2*⁺) and *KD* (*CoV2*⁻)), as compared to early infection groups (*Acute-inf* (*CoV2*⁺), *Acute-inf* (*CoV2*⁻)) and healthy blood donors (CTL). **C.** Heatmap of the cytokines differentially expressed among the patients with postacute hyper inflammation: *MIS-C* (*CoV2*⁺), *MIS-C_MYO* (*CoV2*⁺) versus *KD* (*CoV2*⁻)). **D.** Dot plots of cytokines with a higher expression in the *MIS-C_MYO* (*CoV2*⁺). **B & D**. ρ -values are calculated by Kruskal-Wallis test for multiple comparisons, followed by a post-hoc Dunn's test. * ($\rho < 0.05$), **($\rho < 0.01$), ***($\rho < 0.001$)





Figure S2: Immunoglobulin and cytokine analyses. Related to Figure 2. A. SARS-CoV-2 specific immunoglobulins (IgG, left panels; IgA, right panels) were dosed in the plasma of the different groups, by two methods: S Flow and Tri ELISA. **B** - **G.** Dot plots of cytokines differentially expressed and grouped based on the description of each sub panel. ρ values are calculated by Kruskall-Wallis test for multiple comparisons, followed by a post hoc Dunn's test. *($\rho < 0.05$), **($\rho < 0.01$), ***($\rho < 0.001$). **H.** Hierarchical clustering of cytokines differentially expressed among the patients of the *MIS-C_MYO (CoV2⁺)* group without (red square) or with glucocorticosteroid treatment (black square) before blood sampling.



0.0

0.0


T

0


÷


Figure 3: CyTOF and SC-RNA-SEQ characterization of peripheral blood immune cell (PBMCs) distribution. A. Upper panel: UMAP of 1,150,000 single cells from PBMCs of 7 CTL, 1 *Acute-inf* ($CoV2^-$), 4 *Acute-inf* ($CoV2^+$), 2 *MIS-C* ($CoV2^+$), 6 *MIS-C_MYO* ($CoV2^+$) and 3 *KD* ($CoV2^-$) donors, following analyses by CyTOF and displayed as 23 clusters identified using the individual expression of 29 proteins, as described in Figure S3A. Bottom panel: boxplots of clusters with significant differences observed between groups. **B.** Upper panel: UMAP of 152,201 single cells following extraction from PBMCs (9 CTL, 1 *Acute-inf* ($CoV2^-$), 4 *Acute-inf* ($CoV2^+$), 6 *MIS-C_MYO* ($CoV2^+$), and 3 *KD* ($CoV2^-$)) and processed by SC-RNA-SEQ. A resolution of 0.8 allows to segregate cells into 26 clusters identified based on the expression of several markers and gene signatures, as shown in Figure S4B. Bottom panel: Boxplots of clusters with significant differences.

A & B. (CTL, green; *Acute-inf* (*CoV2*⁻), gray; *Acute-inf* (*CoV2*⁺), blue; *MIS-C* (*CoV2*⁺), orange; *MIS-C_MYO* (*CoV2*⁺), red; *KD* (*CoV2*⁻), pink). In the boxplots, each dot represents a sample. Boxes range from the 25th to the 75th percentiles. The upper and lower whiskers extend from the box to the largest and smallest values respectively. Any samples with a value at most x1.5 the inter-quartile range of the hinge is considered an outlier and plotted individually. ρ values are calculated by Kruskal-Wallis test for multiple comparisons, followed by a post hoc Dunn's test. * ($\rho < 0.05$), **($\rho < 0.01$), ***($\rho < 0.001$).



С CyTOF - PBMCs






60


40


20

D









CM CD4

Treg

20

15

10

5


2.0


1.5


1.0

0.5

0.0








10

20

15

10


T





4. EM CD4

15. NK CD56bright

23. CD4neg CD8neg T cells










30


20


10

















13. gd T cells





10

5










20

15

10

0



	Kruskal-Wallis, p = 0.06
40 -	
30 -	
20 -	
10 -	ᄚᆕᆞᄫᄚ
0 -	╺╼╸╵╺┛┯╸

8. Memory B cells

25. Progenitors

É

7. EM CD8

40

30

20

20

15

0.2 ÷

0.0






Figure S3

6

Figure S3: Identification of cell clusters and PBMCs distribution. Related to Figure 3. A.

UMAP showing all cell surface proteins measured by CyTOF to identify clusters displayed in Figure 3A. **B.** Heatmap of the genes (y axis) used in SC-RNA-SEQ to identify clusters of the UMAP in Figure 3B. Color scale represents scaled expression of the genes. Red and blue indicate high and low expression respectively. **C & D.** Boxplots showing the percentage of cell populations from CyTOF (C) and SC-RNA-SEQ (D). Among the *MIS-C_(CoV2⁺)* group, one patient was diagnosed with a primary Epstein Barr viral infection, characterized at the cellular level by an increase of CD4, CD8 effector memory T cells, Tregs and also proliferating cells.

(CTL, green; *Acute-inf* (*CoV2*⁻), gray; *Acute-inf* (*CoV2*⁺), blue; *MIS-C* (*CoV2*⁺), orange; *MIS-C_MYO* (*CoV2*⁺), red; *KD* (*CoV2*⁻), pink). In the boxplots, each dot represents a sample. Boxes range from the 25th to the 75th percentiles. The upper and lower whiskers extend from the box to the largest and smallest values respectively. Any samples with a value at most x1.5 the interquartile range of the hinge is considered an outlier and plotted individually. ρ values are calculated by Kruskal-Wallis test for multiple comparison, followed by a post hoc Dunn's test. *($\rho < 0.05$), **($\rho < 0.01$), ***($\rho < 0.001$).






Figure 4: Genes and pathways differentially regulated in acute infection and postacute hyper inflammation following SARS-CoV-2 infection. A & B. Bar charts of the number of up- and downregulated genes in Acute-inf $(CoV2^+)$ (A) and All MIS-C (MIS-C $(CoV2^+)$ and MIS-C MYO (CoV2⁺)) (B), compared to CTL, in PBMCs, monocytes/DCs, T and B cells clusters obtained following SC-RNA-SEQ experiments as displayed in Figure 3B. PBMCs represent all clusters; monocytes/DCs cells, clusters 5, 11, 12, 17, 20, 21, 24; T cells, clusters 0, 1, 2, 4, 6, 7, 10, 13, 14, 15, 16, 18 and 23; and B cells, clusters 3, 8, 9, 19, and 22. The top value on the light-colored bars represent the upregulated genes and the bottom dark represent the downregulated genes. **B.** Heatmap of the canonical pathways, enriched in the differentially expressed genes (DEG) from the comparisons performed in A and B in PBMCs, monocytes/DCs, T and B cells, obtained by using Ingenuity Pathways Analysis (IPA) analyses. Left panel, part 1 and right panel part 2. Symbols are used in front of the pathways to represent pathways belonging to the same functional groups. Pathways with an absolute z-score ≤ 2 or adjusted p-value > 0.05 in all conditions were filtered out. Z-score > 2 means that a function is significantly increased (orange) whereas a Z-score < -2 indicates a significantly decreased function (blue). Grey dots indicate non-significant pathways ($\rho > 0.05$).

В


А



С



D



 ▲ Interfe ★ NFκB ● Actin 	tive stress PBMCs		Acute-Inf (CoV2+)				te-Inf (CoV2 ⁻)	vs CTL
	Activation z-score -5,014 3,800	_	Ā		_	_	Act	
	xidative Phosphorylation	Ē						
	MGB1 Signaling -6 Signaling							
	Ic42 Signaling							
🔵 Fo	γ Receptor-mediated Phagocytosis in Macrophages and Mor							
	ARa/RXRa Activation							۰.
	egulation of Actin-based Motility by Rho -1 Signaling	-		-				
	egulation Of The Epithelial Mesenchymal Transition By Growt							
	ute Phase Response Signaling							
	drenomedullin signaling pathway							
	/IP signaling pathway :tin Cytoskeleton Signaling			-			-	
	gulation Of The Epithelial Mesenchymal Transition In Develo						1	
NC	GF Signaling							
	F1α Signaling							
	:DF Signaling :F Signaling							
🔶 Co	pronavirus Pathogenesis Pathway							
	-κΒ Signaling							
	NK Signaling in Osteoclasts docannabinoid Developing Neuron Pathway							
	hite Adipose Tissue Browning Pathway							
	!Y Purigenic Receptor Signaling Pathway Irdiac Hypertrophy Signaling							
	18 MAPK Signaling						1	
	elanocyte Development and Pigmentation Signaling							
	imoylation Pathway hibition of ARE-Mediated mRNA Degradation Pathway							
	RF2-mediated Oxidative Stress Response			-				
	T3 Signaling in Hematopoietic Progenitor Cells							
	OS Signaling 10A Signaling			•				
	pe I Diabetes Mellitus Signaling					•	E.	
	GF Signaling						۰,	
	tegrin Signaling elaxin Signaling							
	rombin Signaling							
	17 Activation Pathway						۰,	
	elin Signaling in Neurons -23 Signaling Pathway							
Ca	rdiac Hypertrophy Signaling (Enhanced)							
	ble of IL-17F in Allergic Inflammatory Airway Diseases ukocyte Extravasation Signaling			_			۰,	
	sulin Secretion Signaling Pathway							
🔵 Rh	noGDI Signaling							
	EM1 Signaling bB2-ErbB3 Signaling						-	
	endritic Cell Maturation							
	lcium-induced T Lymphocyte Apoptosis							
	opamine-DARPP32 Feedback in cAMP Signaling xs Signaling							
	DK5 Signaling							
	AR Signaling							
	ridoxal 5'-phosphate Salvage Pathway enescence Pathway			-				
	nfolded protein response							
	040 Signaling				•			
	F2 Signaling stemic Lupus Erythematosus In T Cell Signaling Pathway		•					
Ro	ble of NFAT in Cardiac Hypertrophy							
	ngiopoietin Signaling euregulin Signaling		•				•	
	euroinflammation Signaling Pathway							
	APK/JNK Signaling							
	ntioxidant Action of Vitamin C rtotoxic T Lymphocyte-mediated Apoptosis of Target Cells	÷		•				
	pe II Diabetes Mellitus Signaling		÷			•		
	enobiotic Metabolism CAR Signaling Pathway							•
	-17A Signaling in Airway Cells C Signaling				•			•
ST	AT3 Pathway							
	IF-mediated Glucocorticoid Regulation	•		•				•
	steoarthritis Pathway -8 Signaling							
He	epatic Fibrosis Signaling Pathway	•						
	OS-iCOSL Signaling in T Helper Cells					•		
	R/RXR Activation oduction of Nitric Oxide and Reactive Oxygen Species in Ma	•		•	•			
🚖 NF	F-κB Activation by Viruses							•
	elatonin Signaling IF Regulation of Innate Immunity	•		•				
	IF Regulation of Innate Immunity ITF Signaling			÷				•
An	ntiproliferative Role of TOB in T Cell Signaling	÷	•		٠			ŀ
	γRIIB Signaling in B Lymphocytes AN Signaling		:		•	•		:
	ukotriene Biosynthesis		•	•	•	•		• •

Figure S4: Genes and pathways differentially regulated from SC-RNA-SEQ in acute infection and postacute hyperinflammation when comparing patients with or without evidence of SARS-CoV-2 infection. Related to Figure 4. A. Bar charts of the number of upand downregulated genes in *Acute-inf* (*CoV2⁻*) compared to CTL, in PBMCs, monocytes/DCs, T and B cell clusters obtained following SC-RNA-SEQ experiments as displayed in Figure 3B. B. Heatmap of the canonical pathways obtained with IPA from DEGs of *Acute-inf* (*CoV2⁺*), as shown in 4A or of *Acute-inf* (*CoV2⁻*), S4A, compared to CTL in PBMCs, monocytes/DCs, T and B cells. C. Bar charts of the number of up- and downregulated genes in *All MIS-C* (*CoV2⁺*) compared directly to *KD* (*CoV2⁻*), in PBMCs, monocytes/DCs, T and B cells. D. Heatmap of the canonical pathways obtained with IPA from DEGs of *All MIS-C* (*CoV2⁺*) compared directly to *KD* (*CoV2⁻*) in PBMCs, monocytes/DCs, T and B cells.


A & C. The top value on the light-colored bars represent the upregulated genes and the bottom dark represent the downregulated genes.

B & D. Symbols are used in front of the pathways to represent pathways belonging to the same functional groups. Pathways with an absolute z-score ≤ 2 or adjusted p-value > 0.05 in all conditions were filtered out. Z-score > 2 means that a function is significantly increased (orange) whereas a Z-score < -2 indicates a significantly decreased function (blue). Grey dots indicate non-significant pathways ($\rho > 0.05$).

С

NF-kB signaling pathway


NF-kB signaling pathway predicted activation





В

A

NF-KB signaling pathway







Expression of NFkB inhibitors in monocytes/cDCs/pDCs

Е




Figure 5

Figure 5: NF-κB signaling pathway activation in acute infection and postacute hyperinflammatory illness. A. Heatmap of the activation of NF-κB signaling pathway, as predicted by IPA, in each disease group compared to controls. Color scale represents the zscore of the prediction. The higher the score, the more activated the NF-κB signaling pathway. "NS" indicates non-significant comparisons. **B & C.** NF-κB signaling pathway from the IPA software, displayed in the monocytes/DCs cells in *Acute-inf (CoV2⁺)* versus CTL (B) or *All MIS-C (CoV2⁺)* versus CTL (C). Changes in gene expression are represented by the log fold change (increase in red and decreased in green). **D.** Dot plot of the expression in monocytes/DCs cells of the positive (from *NFKB2 to REL*) and negative regulators (from *TNFAIP2* to *NFKBIZ*) of NF-κB complex in all disease groups. **E.** Dot plot of the expression in monocytes/DCs of the negative regulators of NF-κB complex in the MIS-C groups.

bioRxiv preprint doi: https://doi.org/10.1101/2021.02.23.432486; this version posted February 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.




Figure S5: NF-κB signaling pathway activation in acute infection and postacute hyperinflammatory illness unrelated to SARS-CoV2 infection. Related to Figure 5. A & B. NF-κB signaling pathway from the IPA software, displayed in the monocytes/DCs cells in *Acute-inf* (*CoV2⁻*) versus CTL (A) or *KD* (*CoV2⁻*) versus CTL (B). Changes in gene expression are represented by the log fold change (increase in red and decrease in green). C & D. Dot plot of the expression in B cells (C) or T cells (T) of the positive (from *NFKB2 to REL*) and negative regulators (from *TNFAIP2* to *NFKBIZ*) of NF-κB complex in all disease groups.






Figure 6: Key pathways and genes deregulated in monocytes/DCs cells of MIS-C_MYO (CoV2⁺) compared to MIS-C (CoV2⁺). A & B. Type-I and type-II interferon signaling pathways from the IPA software. Changes in gene expression are represented by the log fold change in monocytes/DCs cells of *MIS-C* (*CoV2⁺*) (A) or *MIS-C_MYO* (*CoV2⁺*) (B) compared to CTL (red color represents an upregulation, green a downregulation and white no changes). **C.** Dot plot of the MHC class II-associated genes. **D.** Dot plot of the 49 genes from the TNF-alpha Signaling via NF-κB pathway (pathway enrichment analysis by MSigDB Hallmark 2020 (Figure S6E)). **E.** Dot plot of the 27 genes from the Hypoxia pathway (pathway enrichment analysis by MSigDB Hallmark 2020 (Figure S6E)). **F.** Dot plot of the calcium binding genes of the S100 family in CTL, *MIS-C* (*CoV2⁺*) and *MIS-C_MYO* (*CoV2⁺*)


C - **F**. The expression is represented by the centered scale expression of each gene. The "percent expressed" represents the percentage of cells that express the gene.











Adjusted p-value 0.00005 0.00015

600

Е





 Figure S6: Pathway enrichment analysis in MIS-C (CoV2⁺) with or without severe myocarditis. Related to Figure 6. A. Bar charts of the number of up- and downregulated genes in MIS-C (CoV2⁺) (left) and MIS-C MYO (CoV2⁺) (right) compared to CTL in PBMCs, monocytes/DCs, T and B cells. B. Heatmap of the canonical pathways obtained with IPA from DEGs of MIS-C (CoV2⁺) or MIS-C MYO (CoV2⁺) compared to CTL in PBMCs, monocytes/DCs, T and B cells. Symbols are used in front of the pathways to represent pathways belonging to the same functional groups. Pathways with an absolute z-score ≤ 2 or adjusted pvalue > 0.05 in all conditions were filtered out. Z-score > 2 means that a function is significantly increased (orange) whereas a Z-score < -2 indicates a significantly decreased function (blue). Grey dots indicate non-significant pathways ($\rho > 0.05$). C. Bar charts of the number of up- and downregulated genes in MIS-C_MYO (CoV2⁺) compared to MIS-C (CoV2⁺) in PBMCs, monocytes/DCs, T and B cells. D. Bar charts of the top 10 pathways from Reactome_2016, predicted in EnrichR to be modulated by the downregulated genes in the monocytes/DCs cells of MIS-C_MYO ($CoV2^+$) compared to MIS-C ($CoV2^+$). Pathways are ranked based on combined score. E. Bar charts of the Transcription factors from TRRUST database (top) and the top 10 pathways from MSigDB_Hallmark_2020 (bottom) predicted in EnrichR to be modulated by the genes upregulated in monocytes/DC of MIS-C_MYO ($CoV2^+$) compared to MIS-C ($CoV2^+$). Pathways are ranked based on combined score; Transcription factors are ranked based on adjusted p-values.

A & C. The top values on the light-colored bars represent the upregulated genes and the bottom dark represent the downregulated genes.

D & E. *($\rho < 0.05$), **($\rho < 0.01$), ***($\rho < 0.001$), ****($\rho < 0.001$)






SignatureSCORE

116 genes



SignatureSCORE based on the top genes from the RankingSCORE






Figure 7: Identification of genes specifically upregulated in monocytes/dendritic cells of children of the MIS-C_MYO (CoV2⁺) group. A. Schematic representation of the different strategies used to extract 329 unique markers of the MIS-C MYO (CoV2⁺) group from the monocytes/DCs clusters obtained from the single-cell dataset. Strategy 1: direct comparison of the monocytes/DCs cells of the *MIS-C_MYO* (*CoV2*⁺) group to all other samples. Strategy 2: direct comparison of the monocytes/DCs cells of MIS-C_MYO (CoV2⁺) to other samples with postacute hyperinflammation (MIS-C (CoV2⁺) and KD (CoV2⁻)). Strategy 3: selection of the genes upregulated only in the monocytes/DCs cells of MIS-C_MYO (CoV2⁺) when compared to CTL. Below each strategy, the corresponding dot plot obtained from SC-RNA-SEQ, with the number of upregulated genes. The average expression is represented by the centered scale expression of each gene. On the left, name of each group with its corresponding color is shown. **B.** Heatmap of expression of the 116/329 genes with a higher expression in *MIS-C_MYO* $(CoV2^+)$ than in other groups in the bulk dataset. Color scale indicates the scaled GeneSCORE (mean z-score of the gene in all samples of a group), with red and blue representing the highest and lowest expressions respectively. Hierarchical clustering of the genes was computed with a Pearson's correlation as a distance. C. Box plot of the expression of the 116 genes validated in C, calculated as a SignatureScore. SignatureScore represents for each sample the mean z-score of the 116 genes selected in B in the bulk-RNA-SEQ dataset. (Explained in Figure S7A). D. Boxplot showing the SignatureScore computed on the expression of the top 25 genes, as ranked in Figure S7B, in the Bulk-RNA-SEQ dataset.

C & D. Each dot represents a sample. Boxes range from the 25th to the 75th percentiles. The upper and lower whiskers extend from the box to the largest and smallest values respectively. Any samples with a value at most x1.5 the inter-quartile range of the hinge is considered an outlier and plotted individually.

В

0.4


0.0


-0.4


-0.8















Figure S7

Figure S7: SignatureScore and top genes correlated with the occurrence of myocarditis in MIS-C (CoV2⁺). Related to Figure 7. A. MIS-C_MYO (CoV2⁺)-specific genes were scored (GeneSCORE) by adding their expression values (as z-scores) in each sample, divided by the total number of samples. Similarly, a SignatureSCORE was derived for each sample as the mean z-score of these samples. From these two scores, a RankingScore was calculated by subtracting the GeneScore of the MIS-C ($CoV2^+$) and the CTL groups to the GeneSCORE of the MIS-C_MYO (CoV2⁺) group. **B.** Top: Barplot of the RankingScore of each gene. Red, green and orange barplots: GeneScore of the MIS-C_MYO (CoV2⁺)-specific genes in the MIS- C_MYO (CoV2⁺), CTL and MIS-C (CoV2⁺) groups respectively. Genes are ranked based on their RankingScore as explained in S7A C. Curated analyses based on literature regarding the known links between the top 25 genes, and inflammatory response, myocarditis, oxidative stress, TNF-α, NF-κB, MIS-C or Kawasaki disease, SARS-CoV-2 and/or COVID-19. On the Y axis, genes are positioned from top to bottom following their rank (Top = ranked 1). A blue dot means strong links between the gene and the pathway (on the X axis) were found in peerreviewed scientific publications. D. Heatmap of the expression of the genes of the S100A family, extracted from Bulk-RNA-SEQ, from PBMCs. Color scale indicate the scaled GeneSCORE (mean z-score of the gene in all samples of a group), with red and blue representing the highest and lowest expressions respectively. Hierarchical clustering of the

genes was computed with a Pearson's correlation as a distance.



В




Figure S8. A & B. Graphical representation based on cytokines, cellular and transcriptomic analyses (part above black dotted line), combined with known literature (part under the black dotted line), illustrating a putative model explaining the occurrence of myocarditis among children in the *MIS-C* (*CoV2*⁺) group. **A.** model based on the *MIS-C* (*CoV2*⁺) group and **B.** model based on the *MIS-C_MYO* (*CoV2*⁺) group. Black writing represents genes and functions both modulated in the *MIS-C* (*CoV2*⁺) and *MIS-C_MYO* (*CoV2*⁺) groups compared to CTL, whereas green and red are highlighting genes and pathways differentially modulated in the *MIS-C_MYO* (*CoV2*⁺) groups, respectively.